Assessment of patients with late diagnosis and missed opportunities in the Swedish HIV-1 epidemic by Brännström, Johanna
From the Unit of Infectious Diseases                                 
DEPARTMENT OF MEDICINE HUDDINGE 
 
Karolinska Institutet, Stockholm, Sweden 
ASSESSMENT OF PATIENTS WITH  
LATE DIAGNOSIS AND MISSED OPPORTUNITIES  
IN THE SWEDISH HIV-1 EPIDEMIC 
Johanna Brännström 
 
Stockholm 2016 
 
 All previously published papers were reproduced with permission from the publisher. 
Published by Karolinska Institutet. 
Printed by E-Print AB 
© Johanna Brännström, 2016 
ISBN 978-91-7676-196-0 
Assessment of patients with late diagnosis and 
missed opportunities in the Swedish                
HIV-1 epidemic 
 
THESIS FOR DOCTORAL DEGREE (Ph.D.) 
By 
Johanna Brännström 
MD 
 
Principal Supervisor: 
Professor Anders Sönnerborg 
Karolinska Institutet 
Department of Medicine, Huddinge 
Unit of Infectious Diseases 
 
Co-supervisor(s): 
Dr. Veronica Svedhem Johansson   
Karolinska Institutet 
Department of Medicine, Huddinge 
Unit of Infectious Diseases 
 
Dr. Gaetano Marrone 
Karolinska University Hospital 
Department of Infectious Diseases 
 
Opponent: 
Dr. Matti Ristola 
University of Helsinki 
Department of Clinical Medicine 
 
 
Examination Board: 
Associate professor Hans Norrgren 
University of Lund 
Department of Clinical Science 
Division of Infection Medicine 
 
Associate professor Jens Boman 
University of Umeå 
Department of Clinical Microbiology 
  
Associate professor Carl-Johan Treutiger 
Karolinska Institutet 
Department of Medicine, Huddinge 
Centre of Infectious Medicine 

 
 
 
 
 
To my family 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
It is bad enough that people are dying from AIDS,  
but no one should die of ignorance. 
(Elisabeth Taylor, 1986)  
 
 
 
 
 
ABSTRACT 
Discovered in 1983, with a possibility to diagnose since 1985, and with efficient treatment 
existing now for two decades, HIV-1 still ranks among the top ten causes of death globally. 
Approximately 40 million people are living with HIV-1 worldwide; almost half still not 
diagnosed. In Europe one third are estimated to be unaware of their infection and half are 
diagnosed late, with consequences in terms of increased morbidity, mortality, risk of onward 
transmissions and higher health care costs. The aim of this thesis was to assess the extent of 
late diagnosis of HIV-1 infection in Sweden and to analyse whom gets diagnosed late and 
why.  
For Paper I we conducted a retrospective study of all patients diagnosed with AIDS (n=487), 
reported to the Swedish Centre of Infectious Disease Control (SMI) 1996-2002, concluding 
that the patients diagnosed late (here defined as simultaneous HIV/AIDS) represented an 
increasing proportion of patients with AIDS in Sweden. Migrants, persons infected 
heterosexually and persons aged over 40; all had a higher probability of a late diagnosis.  
For Paper II we conducted a cross-sectional national cohort-study including all newly HIV-1 
diagnosed patients at 12 Swedish clinics. Data were collected from the National quality 
register InfCare HIV (n=575) and additional questionnaires (n=409) from the clinics. 58% 
were Late Presenters (LP), presenting for care with CD4+ T-cells < 350/mm3 +/- AIDS. Age 
(with increasing odds by increasing age) or being a migrant had a distinct association with 
being a LP. Half of the migrants had lived in Sweden for > 1 year at diagnosis and two thirds 
had a missed opportunity at immigration. However, if born abroad, but reported to be infected 
in Sweden, there was no difference in LP compared to the Swedish born. One quarter of all 
patients had missed opportunities within Swedish healthcare, presenting with HIV- and/or 
AIDS-associated symptoms, without an offer of HIV-testing. 16% had a history of self-
neglected symptoms. 
In Paper III we further analysed the missed presentations at seeking healthcare, the HIV- and 
AIDS- associated symptoms neglected by the patients and also assessed the initiator of the 
HIV-test. Migrants were less likely both to neglect their symptoms and to be missed at health 
care compared to individuals born in Sweden. Also men who have sex with men (MSM) 
were less likely to neglect their symptoms compared to those with a heterosexually acquired 
infection. Patients with a history of drug use, a previous negative test (mainly MSM) and 
those infected abroad were more likely to take the initiative to test, whereas the opposite held 
for patients >50 years and those previously missed at presentation.  
The predominance of migrants in Papers II-III, and results indicating that the number of 
domestic infections might be underestimated in this group, made us want to investigate this 
further. In Paper IV we applied a CD4+ T-cell decline trajectory model to a subsample of the 
Swedish migrant cohort (n= 1244) to compare estimates of country of HIV acquisition with 
the clinical reports. The model estimated that 17% had acquired the HIV infection after 
immigration, whereas the doctor’s estimate was 11%. Phylogenetic analysis was performed 
in discordant patients to explore whether this would favour the model or the doctor’s 
estimate. A higher concordance was found with the CD4 model estimates than with the 
clinical reports (30% vs. 17%).  
In summary my thesis shows a high proportion of late HIV-1 diagnosis in Sweden, but also 
emphasizes that there are several opportunities to improve this. Activities to increase societal 
awareness, continuous promotion and normalization of the HIV-test, education of health care 
professionals including further implementation of indicator-guided testing and an extended 
testing and primary prevention aimed at migrants are all important steps forward.   
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1 PREFACE 
 
Why HIV became my main field of interest & the background of this thesis: 
Growing up, being an adolescent, in the eighties and meeting information about HIV and 
AIDS almost anywhere made a deep impression on me. Lucky to have the most inspiring and 
engaged biology teacher, daring to confront the problem, I was early involved in vivid 
discussions from basic virology to the social stigma. A few years later, in parallel with 
medical studies in the early 90´s, meeting the epidemic “real life” while going clubbing in the 
gay Stockholm, dealing with the complex mix of party and fear, made imprints for life. 
Suddenly seeing the big miracle with the introduction of protease-inhibitors happening to be a 
medical student at the clinic of Infectious diseases at Danderyd hospital in 1996 was amazing. 
Everything was looking bright, but then, as a newly fledged specialist in Infectious diseases 
several years later, deciding to specialize in HIV, I still met very sick patients… My first 
strong impression was a woman my own age having been ill for years with skin problems, 
fungal infections, anaemia and weight loss finally sent into the Clinic of Infectious Diseases 
for recurrent pneumonias. In spite of several contacts with the Swedish health care system no 
one had had a thought of HIV. 
 
There were still many challenges… 
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2 INTRODUCTION 
 
2.1 GENERAL ASPECTS OF LATE HIV-1 DIAGNOSIS 
Despite advances in prevention, diagnostics and treatment, the human immunodeficiency 
virus (HIV) is still one of the leading deaths causes worldwide and remains one of the most 
important communicable diseases in Europe. Estimates show that as many as one third of 
HIV-1 positive individuals living in the European region could be unaware of their diagnosis 
and about half are diagnosed late [1, 2] with consequences in terms of increased morbidity, 
mortality [3], an increased risk of onward transmission [4] and consequently also higher 
health care costs [5].  
There is extensive research on vaccination and cure on-going [6], but still, in the absence of 
this, early diagnosis and treatment is one of the most important approaches to reduce HIV-
related morbidity and to control the HIV epidemic.  
The reasons for late diagnosis of HIV-1 are many and diverse. The overall aim of this thesis 
was to assess the situation in Sweden by quantifying the proportion diagnosed late, 
identifying risk indicators associated with a late diagnosis and to identify opportunities for an 
earlier care of our patients. 
As a HIV clinician I have had a special focus on the clinical manifestations of the disease and 
how I could contribute to enhance earlier diagnosis by assessing the doctors’ and patients’ 
delay, respectively. Thus a substantial part of the background also deals with the different 
phases of infection and what clinical signs and laboratory findings it is important to pay 
attention to. The large proportion of migrants among our patients, and a general interest in 
public health and communicable disease control, also made me raise my eyes and incorporate 
missed opportunities on the societal level by assessing the diagnosis of HIV-1 infection in 
migrants from high endemic countries. 
 
 
2.2 HIV HISTORY 
The first official report on what was later to be known as HIV/AIDS, was published in 1981 
[7], describing 5 cases of unusual lung infection, Pneumocystis carinii (later known as 
Pneumocystis jirovecii) pneumonia (PCP) in homosexual men, in Los Angeles, USA. Shortly 
similar cases, including a cluster of Kaposi’s sarcoma among homosexual males in other 
cities, were reported. Among these were also diagnoses of candida infections, severe herpes 
infections, PCP, cryptococcal meningitis and cerebral toxoplasmosis, all signs of an impaired 
immune system [8-11]. 
Speculation and theories of the cause of the disease were many and imaginative, not seldom 
coloured by prejudice. However, soon it became evident that this disease did not only affect 
homosexuals but also haemophiliacs, people who inject drugs (PWID), males/females from 
Haiti and partners to these as well as children born by women in these groups [12]. In the 
mid-eighties the epidemic in Africa, where HIV have its origin, was observed [13]; HIV-1 
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crossing the art barrier and pass from chimpanzee to human approximately in the 1920/30’ies 
[14]. 
In 1983, the same year as the first Swedish patient with AIDS was identified at Roslagstull’s 
hospital, a human retrovirus was isolated from lymph nodes by the Montagnier/Barré-
Sinoussi group and confirmed by Robert Gallo [15, 16]. The virus, initially called LAV 
(Lymphadenopathy Associated virus)/HTLV-III (Human T-Lymphocyte Virus type III), but 
later renamed as HIV-1, was identified as the causative agent of AIDS. 
The isolation of the virus lead to the first commercial blood test to detect HIV antibodies in 
the blood, ELISA [17, 18], which was licensed 1985. In parallel to the medical progress 
demands of testing in different groups evoke resulting in severe consequences for those 
turning out to be HIV positive, contributing to an already started stigmatization. 
In 1987 the first anti-retroviral drug, zidovudine (zdv), was introduced [19], prolonging life, 
but in retrospect causing problems with viral resistance. In June 1995 the first Protease 
Inhibitor was approved [20] and thereby starting a new era with combination of medications, 
so called, Highly Active Anti-Retroviral Therapy (HAART) or cART (c=combination), 
rapidly reducing AIDS morbidity and mortality rates in those with access to treatment. The 
following year, 1996, PCR methods to measure HIV RNA were introduced and high viral 
loads were seen to be associated with a poorer prognosis [21]. 
From 1996 there is the ability to diagnose, efficiently treat and monitor a HIV infected 
patient. However, people still die of AIDS and the HIV related stigma continues… 
 
 
2.3 THE VIRUS 
HIV is a retrovirus within the genus Lentiviridae (lenti=slow) of the Retroviridae family [22]. 
The virion is composed of two copies of a single-stranded RNA and set of viral proteins, 
including the viral enzymes, and surrounded by a lipid bilayer membrane, originally derived 
from the infected host cell [23] (Figure 1). 
The viral genome is composed of nine genes, out of which the three structural genes; gag, pol 
and env, are the most important. Gag encodes for the major structural proteins (e.g. the matrix 
protein (p17) and the capsid protein (p24)). The pol genes encode for the viral enzymes 
essential for the reverse transcription of RNA to DNA (reverse transcriptase, p64), integration 
of HIV DNA into the human genome (integrase, p32) and cleavage of the HIV proteins 
(protease, p10). Env encodes for the envelope glycoproteins (gp41 and 120), crucial for the 
virus ability to infect the human target cells, by attaching to their CD4 receptors [23, 24] 
(Figure 1). 
The viral enzymes are each important prime therapeutic targets for ART and sequencing of 
the pol gene is recommended to monitor drug resistance. These sequences can also be used in 
constructing phylogenetic trees, a technique used in paper IV. 
There are two main types; HIV-1 and HIV-2, and the prior is what is focused on in this thesis.  
The HIV-1 strains can be classified into four groups, originating from separate introduction 
of simian virus to humans. The “major” group M, constitutes > 90% of all HIV-1 infections 
worldwide. There are also the “outlier” group O and the more rare groups “novel”, N, and P, 
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all mainly restricted to West and Central Africa. The group M is further subdivided into nine 
subtypes or clades; A-D, F-H, J and K [25]. Additionally there are mixtures of these; 
circulating recombinant forms (CRFs) and unique recombinant forms (URFs). HIV-1 
subtype C was first discovered by Professor Sönnerborg’s research team in 1988 [26] and is 
now the most common and constitute half of all infections worldwide [27]. In resource rich 
countries the subtype B historically have been the predominant, but other sub-types are 
becoming more frequent as a result of travels and migration. In Sweden subtype B today 
constitutes less the 50% and recombinant forms are increasing among newly diagnosed [28] 
showing that we are part of the global epidemic.  
 
 
 
Figure 1. The structure and life cycle of HIV . Source: www.study.com/academy 
 
 
2.4 THE HOST AND THE T-HELPER CELL 
By attaching to the CD4 receptor and the chemokine co-receptor CCR5, or in some cases 
CXCR4, the target cells of HIV are entered.  
The most important cells affected by HIV are the CD4+ T-lymphocytes (the “T-helper 
cells”), which have a central role in our immune system by directing a variety functions.  
By destroying and deregulating the CD4+ T-lymphocytes HIV also causes immunologic 
dysfunction of CD8+ T-lymphocytes, B-lymphocytes, natural killer (NK) cells, and non-
lymphoid cells through mechanisms including increased cell turnover, immune activation, 
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differentiation, and homeostatic responses [29]. Together, all these factors lead to severe 
qualitative changes ultimately affecting the overall immunological competence of the host.  
Due to its central role, progression of the HIV disease can easily be measured and evaluated 
by the CD4+ T-lymphocyte cell count, which is widely used as an estimate of the global 
immune competence [30]. This can be expressed as the absolute count, as the ratio CD4/CD8 
or as the percentage of all lymphocytes. The prior is what is normally being used, even 
though the ratio has proved to be a better and more stable predictor of the immune pathology 
associated with HIV infection [31]. In non HIV-infected adults/adolescents normal CD4+ T-
cell counts ranges from 490–1340 cells/mm3 (corresponding to 1.13-3.93 or 35-59%, 
according to the Clinical Immunology and Transfusion Medicine, Karolinska University 
Hospital.  
 
 
2.5 THE NATURAL COURSE OF HIV-1 INFECTION 
2.5.1 Transmission 
HIV is present in all body fluids of an HIV infected individual including blood, semen, pre-
seminal fluid, vaginal fluids, rectal fluids and breast milk and is usually divided into four 
main routes of transmission; heterosexual contact, men who have sex with men (MSM), 
intravenous drug use (IDU) and mother to child transmission (MTCT). The later occurs 
predominantly at birth and by breastfeeding. Rarely, these days (after the introduction of 
screening for HIV antibodies in donated blood), it may also be transmitted by blood-products 
and transfusions. 
Transmission rates from an untreated individual are highest by parental exposure and 
historically, before blood donor screening, blood transfusion was associated with nearly a 
100% risk [32]. The risk of MTCT varies from 15-45%, whether the mother is breastfeeding 
or not, whereas for people who inject drugs (PWID) the risk of transmission per 
contaminated injection is estimated to 0.6-0.8%. Sexual transmission risk at mucosal 
exposure are reported to range widely from 3.4 to less than 0.05% and vary according to the 
site of exposure; rectal mucosa > vaginal mucosa > oral mucosa [33, 34]. Local 
inflammation, particularly in the presence of ulcers, increases the risk, just as the amount of 
body fluid and the magnitude of the inoculum (i e the level of plasma HIV RNA) [35]. The 
risk of transmission is also influenced by the innate immunity of the host [36]. 
 
2.5.1 Primary infection 
After transmission, the virus disseminates to lymphoid tissues and replicates aggressively. 
Persistent viral reservoirs, with integration of viral DNA, predominantly in memory T-cells, 
are established almost instantly and the chronic infection is a fact [37]. 
The initial high viral replication may manifest itself through the acute HIV syndrome within 
one to four weeks after infection (Figure 2). This, often flu- or mononucleosis- like illness, 
known as acute or primary HIV infection (PHI), may last from a few days up to a month. 
However, the symptoms of PHI may also be mild enough to go completely unnoticed.  
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In the absence of ART the viremia peaks at about three to four weeks post exposure [38]. 
This is usually associated with a pronounced depletion of susceptible CD4+ T-cells in the 
body, primarily in the Gut Associated Lymphoid Tissue (GALT), but also in the peripheral 
blood [29, 39]. In rare cases the immunosuppression may become so severe, already at this 
stage, that the patient may develop AIDS defining conditions (see 2.5.4.1. below). 
Due to the high viral replication the risk of onward transmission is very high and the newly 
infected individuals may actually be the ones mainly driving the epidemic [40]. 
 
2.5.1.1 Possible symptoms of Primary HIV-1 Infection include: 
§ Fever 
§ Headache 
§ Myalgia/arthralgia  
§ Lymphadenopathy 
§ Pharyngitis 
§ Skin rash 
§ Night sweats 
§ Diarrhea 
§ Oral or genital ulcers 
§ Meningitis/meningoencephalitis, in rare cases. 
 
2.5.1.2 Laboratory findings in Primary HIV-1 Infection: 
§ Anaemia, leukopenia and/or thrombocytopenia is common 
§ Elevated liver enzymes (ASAT/ALAT) 
§ Normal to slightly increased Crp 
§ Elevated LD 
 
 
2.5.2 Chronic asymptomatic infection – “Clinical Latency” 
In parallel with the high viremia an HIV-specific, but incomplete, immune response leads to 
the development of a “steady state” or viral set point, typically reached within a few months. 
The level of this “set point” is an important prognostic factor; the higher viral load at this 
stage the more rapid disease progression [21]. The CD4+ T-cells typically rebounds to higher 
levels after the “steady state” has been reached, but seldom to its previous levels.  
The above is followed by an asymptomatic chronic infection, where there is a sustained lower 
viral replication and immune activation [29]. During this phase there is a progressive loss of 
CD4+ T-cells (Figure 2). The mechanisms behind this depletion of T-cells have for many 
years been uncertain. Recently however it has been shown that only a minority, 5%, of dying 
cells are productively infected and die by apoptosis, whereas the remaining die by pyroptosis, 
a pro-inflammatory programmed cell death, rather to compare with a “cell-suicide”, by which 
the cell prevents itself from becoming infected [41].   
During this “clinical latency” stage of the HIV infection the circulating levels of HIV-virus in 
the blood are normally low, in rare cases even undetectable. Apart from a persistent 
lymphadenopathy, in some individuals, the infection normally remains asymptomatic until 
the CD4+ T-cells decrease to < 350 cells/mm3. The duration of this “latency” period may last 
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from a year or two to > 15 years in the so-called long term non progressors [42]. The rate of 
disease progression is dependent both on factors of the host (e.g. different HLA alleles and 
mutations of the CCR5 receptor [39]) and of the viral fitness, where the speed of the viral 
replication is directly correlated to a faster disease progression (Figure 3).  
Importantly, during this asymptomatic stage the patient also is infectious to others.  
 
Figure 2. Time-based 
progression of untreated 
HIV infection, demon-
strated by CD4+ T-cell 
count and viral load. 
Adapted from Fauci and 
Pantaleo, 1993 [43]. 
 
 
 
 
 
 
2.5.3 Chronic symptomatic infection 
By time, as the CD4+ T-cells successively decrease and the immune system deteriorates, the 
“steady state” is eventually lost and the viral load increasing. In parallel with this the patient 
also becomes symptomatic (Figure 2). 
Some of the early symptoms may be temporary and/or possible to treat and may be followed 
by more asymptomatic years and are thus important to recognize and pay attention to. Later 
constitutional symptoms develop. 
 
2.5.3.1 Early symptoms in HIV-1 infection: 
§ Varicella Zoster 
§ Seborrhoea 
§ Oral candida 
§ Hairy Leukoplakia 
 
2.5.3.2 Later, constitutional, symptoms in HIV-1 infection: 
§ Fatigue 
§ Weight loss 
§ Fever, night sweets 
§ Diarrhea 
 
2.5.3.3 Laboratory findings in symptomatic chronic HIV-1 infection: 
§ Anaemia, leukopenia and/or thrombocytopenia is common 
§ Elevated erythrocyte sedimentation rate (ESR) 
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2.5.4 AIDS 
Without ART the HIV-infection progresses to AIDS, which is the end-stage of the infection, 
in average after 8-10 years [44]. By the time AIDS develops the immune system is severely 
compromised with the risk of numerous opportunistic infections and development of certain 
cancers or other severe clinical manifestations, which most normally do not affect a healthy 
individual. Any of these infections is per se what is defining AIDS. The development of 
advanced symptoms are often corresponding to a CD4+ T-cell count of less than 200 
cells/mm3, a cut off that per se also are AIDS-defining in the American guidelines [45]. 
Without treatment AIDS leads to an inevitable death, but even with treatment the prognosis is 
much poorer than for someone having initiated treatment early [46]. 
 
2.5.4.1 AIDS-defining conditions: 
§ Candidiasis of bronchi, trachea, or lungs 
§ Candidiasis of oesophagus† 
§ Cervical cancer, invasive§ 
§ Coccidioidomycosis, disseminated or extra pulmonary 
§ Cryptococcosis, extra pulmonary 
§ Cryptosporidiosis, chronic intestinal (>1 month's duration) 
§ Cytomegalovirus disease (other than liver, spleen or nodes) 
§ Cytomegalovirus retinitis (with loss of vision)† 
§ Encephalopathy, HIV related 
§ Herpes simplex: chronic ulcers (>1 month's duration) or bronchitis, pneumonitis, or 
esophagitis  
§ Histoplasmosis, disseminated or extra pulmonary 
§ Isosporiasis, chronic intestinal (>1 month's duration) 
§ Kaposi sarcoma† 
§ Lymphoma, Burkitt  
§ Lymphoma, immunoblastic 
§ Lymphoma, primary, of brain 
§ Mycobacterium avium complex or Mycobacterium kansasii,  
disseminated or extra pulmonary† 
§ Mycobacterium tuberculosis of any site, pulmonary,†§  
disseminated,† or extra pulmonary† 
§ Mycobacterium, other species or unidentified species,  
disseminated† or extrapulmonary† 
§ Pneumocystis jirovecii pneumonia† 
§ Pneumonia, recurrent†§ 
§ Progressive multifocal leukoencephalopathy 
§ Salmonella septicemia, recurrent 
§ Toxoplasmosis of brain, onset at age >1 month† 
§ Wasting syndrome attributed to HIV 
 
† Condition that might be diagnosed presumptively. § Only among adults and adolescents aged >13 years. 
(CDC. 1993 Revised classification system for HIV infection and expanded surveillance case definition for 
AIDS among adolescents and adults. MMWR 1992;41) 
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Figure 3. HIV and viral 
dynamics, from J Coffin 11th 
International Conference on 
AIDS; 1996; Vancouver, 
Canada. Abstract Th.18. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2.5.4.2 Symptoms of AIDS:  
§ Night sweats 
§ Weight loss 
§ Unexplained fatigue 
§ Persistent fever  
§ Chronic diarrhoea 
§ Skin rashes  
§ Tongue lesions 
§ Cough 
§ Shortness of breath 
§ Headaches 
§ Blurred and distorted vision 
 
 
2.6 DIAGNOSING HIV 
The diagnosis of HIV is primarily based on serology methods, detecting antibodies to the 
virus by an Enzyme Linked Immuno Assay (ELISA). Most commonly, in resource rich 
settings, a combination assay, detecting also the HIV p24 antigen, is being used. An 
infected person is most often reactive in this combination test within 2-3 weeks but a 
follow-up time of six weeks is recommended to exclude HIV infection [47]. If a test is 
reactive a second, more specific immunoassay (immunoblotting or Western blot) is used, 
both to confirm the positive result and to differ between HIV-1 and 2. 
The test has a high sensitivity and specificity, >99%, and results are normally available 
within 24 hours. For even quicker results a rapid test (either on blood or saliva) may be 
used. Also this kind of test has a high accuracy, but have a poorer capacity to catch the 
earliest infections and, in case of a positive result, also require confirmation with 
conventional methods.  
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During a true symptomatic PHI the combo test is always positive, but if there is a high 
suspicion of a very early HIV infection a PCR test to detect the viral RNA can be considered. 
However the window when the combo test is negative and the PCR test is positive consists of 
a few days only shortly after transmission [47]. 
In all patients diagnosed with HIV an additional test on a second blood sample is always 
made before making the diagnosis definite. This is done just to make sure there has been no 
mix up of laboratory samples. 
Despite excellent and also cheap diagnostics too few tests are offered… 
 
 
2.7 HIV TREATMENT   
From having been associated with an imminent death sentence, ART has transformed the 
HIV infection to a treatable chronic disease [48, 49]. 
Since the introduction of the first antiretroviral drug (ARV), zidovudine (zdv) in 1987 
approximately 30 additional drugs, in 6 different classes, have been approved. From 1996, 
when the Protease inhibitors were introduced, it is possible, by combining ARVs with 
different mechanisms of action, to fully suppress the viral replication. By this not only further 
deterioration of the immune system is prevented; it also allows for improvement and 
recovery. The treatment is life long, but even though it cannot cure HIV, it allows for people 
living with HIV to have “healthy and productive lives” and a near to normal life span [50-
53]. Furthermore, a well-treated patient has a negligible risk of transmitting the disease also 
making big implications in terms of prevention (see 3.3.2). 
HIV-1 treatment is normally given by combining 3 different ARVs, where the typical 
combination for many years have consisted of 2 Nucleoside/Nucleotide Reverse 
Transcriptase Inhibitors (NRTIs) in combination with a Non-Nucleoside Reverse 
Transcriptase Inhibitors (NNRTI), a boosted Protease Inhibitor (PI/r) or an Integrase 
Inhibitor (INSTI). Finally there are also Entry/Fusion Inhibitors, mainly used in patients 
with resistance to the other drugs. The last years the INSTI have started to dominate as the 
drug of choice in the newly diagnosed patients, still with 2 NRTIs as backbone, but NRTI 
sparing regimens are being investigated in order to minimize side effects. Studies of the 
“nuce-lite” regimen of lamivudine (3TC) and a boosted PI have recently shown non-
inferiority compared to standard ART [54-56]. Similarly an on-going study, investigating 
dual-therapy with 3TC and INST (dolutegravir), presents promising interim-results [57]. 
Further development of ART drugs is on-going, not the least by finding new formulas of 
existing medications, to allow for fewer side effects and to make them easier to administer. 
When to start ART has been debated since it was first introduced and the approach has 
changed from treating only the most immunocompromised with symptomatic disease, to treat 
also the asymptomatic according to different cut of levels of CD4+ T-cells of 200, 350 and 
500 respectively. During 2015 the START [58] and TEMPRANO [59] studies presented 
evidence in favour of immediate treatment and ART are now recommended to everyone with 
HIV-1 disregarding the CD4+ T-cell count [60-62].  
To fully benefit from ART early diagnosis and initiation is needed… 
 12 
2.8 HIV VACCINATION AND CURE 
Even though modern ART are efficient, easy to administer and associated with minimal side 
effects HIV is still, by many, considered to be associated with several comorbidities due to 
residual viral replication and/or chronic inflammation [63-66]. There is also the obstacle of 
taking drugs, the worries of onward transmission and last but not least the HIV related 
stigma. 
Despite considerable efforts there is still no vaccine for HIV. However, the last years, after 
the functional cure of the Berlin patient, who was declared free of the virus after having 
received two stem cells transplantations against acute myeloid leukaemia (AML), from a 
HLA-matched, unrelated donor homozygous for the CCR5∆32 mutation, in 2007-2008 [67], 
there is now the hope of a cure.  
The mechanisms for HIV persistence are several, all now being addressed in therapeutic 
research, with the unifying theme to reduce the HIV reservoir size [68]. Most likely success 
will require a combination approach like early ART, agents to overcome viral latency, 
therapies that will strengthen the immune response to target the productively infected cells 
and gene therapy, or intensified ART, to protect CD4+ T-cells from infection [69]. 
Early diagnosis is thus also of importance for the possibility of a cure… 
 
 
2.9 THE CONTINUUM OF CARE 
In 2005, nearly a decade after the introduction of the highly efficient cART, attention was 
drawn to the fact that this achievement alone was not good enough and the population 
effectiveness of ART far from sufficient [70]. A model with all the needed steps to reach a 
well treated HIV population was described [70] and then reinforced by Ulett at al 
describing a “Blue-print for HIV treatment success” [71], which highlighted the equal 
importance of identifying the patients (diagnosis), successful linkage to care, access and 
acceptance of ART, adherence and retention in care.  
This model, later to been known as “the HIV care continuum” or the “treatment cascade” 
received a lot of attention in 2011 when it was reported that in such a resource rich country as 
the US only 19% of PLWH reached the goal of an undetectable viral load [72] (Figure 4).  
 
 
Figure 4. The spectrum of engagement in 
HIV care in the United States, from HIV 
acquisition to full engagement in care, 
receipt of antiretroviral therapy, and 
achievement of complete viral suppression. 
By Gardner et al, 2011 [72]. 
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In analogy with this the UNAIDS formulated a global “90-90-90” target in 2014, aiming at 
90% of PLWH diagnosed, 90% of those diagnosed receiving ART and 90 % of those 
receiving ART being virally suppressed by 2020 [73].  
 
 
2.10 HIV IN THE GLOBAL PERSPECTIVE 
At present there are approximately 37 million people living with HIV (PLWH) worldwide 
(Table 1) and more than 34 million individuals are estimated to have died from AIDS related 
causes since the diagnosis of the first case of HIV in 1981. Still accounting for 1.2 million 
deaths in 2014 HIV/AIDS rank among the top ten of death causes globally today [74-76]. 
The majority of PLWH, 70%, live in the sub-Saharan Africa (SSA) and 14 % in the Asia 
and Pacific region, compared to in total 7% in Western and Central Europe and North 
America. Whereas many of the countries in SSA have generalized epidemics and 
heterosexual transmission dominates, sex between men are proportionally more common as 
transmission route in most western countries. In Eastern Europe & Central Asia the 
epidemic is primarily driven by heterosexual transmission and PWID whereas PWID and 
sex workers dominate among the newly diagnosed in Asia and the Carribean. In the Middle 
East and North Africa PWID, MSM and to a lesser extent sex workers dominate and in 
Latin America the most affected populations are MSM, followed by sex workers [74-77]. 
Thanks to the development of ART together with the “2000 United Nations Millennium 
Declaration” [78] and the establishment of initiatives like “The Global Fund to Fight AIDS, 
Tuberculosis and Malaria” [79] and “The United States President’s Emergency plan for 
AIDS relief” (PEPFAR) [80] major achievements have been made. There is now a 
continuous decline in AIDS related mortality and the incidence of new infections has 
similarly declined by 35% since 2000. Still, approximately 2 million people became newly 
infected in 2015 and only about 40% of adults and one third of children with HIV, are 
receiving ART globally [81]. Considering the new “treat all” recommendation [82] and 
taking into account that the delivery of ART only represents one part of the “treatment 
cascade” (see 2.9) this is far from sufficient. Also HIV testing reach is limited and there are 
estimates indicating that almost half of all individuals living with HIV worldwide still 
remains to be diagnosed [83]. 
The relatively greatest accomplishments this far have been made in low and middle-income 
countries, but whereas many of the SSA countries have found measures to control their 
epidemic this is not true for Central Africa and other regions in the world. The 
proportionally largest increase of new infections in recent years has been seen in the Middle 
East and North Africa, but neither in Eastern Europe, with an increase particularly among 
PWID and their sexual partners [84], there are signs of a declining epidemic [83]. Also in 
Western Europe an increase in certain populations, like MSM and older PWID, have been 
reported [85]. In the whole WHO European area the highest number ever, with > 140 000 
newly diagnosed, was reported in 2014 [86]. 
Apart from high-risk groups, such as MSM and PWID, migrants from countries with a high 
HIV prevalence, primarily the SSA, constitute a substantial proportion of PLWH in Europe 
[87, 88]. Regional differences are seen and the contribution of migrant population to 
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national epidemics is diverse with proportions ranging from 75% migrants in Sweden to less 
than 5% in Poland, Slovakia, Romania, Lithuania and Estonia [89]. The majority of these 
migrants are presumed to have acquired their infection in their home country. However, data 
on HIV among the migrant population is scarce. Particularly there is limited data on HIV 
incidence and HIV acquisition after arrival in the new country [90]. 
With increased travels and migration, not the least due to the refugee situation the last year, it 
is important to find measures for a good surveillance of the epidemic, something that I focus 
on in Paper IV. 
 
Region Total n (%) PLWH Newly Infected 
Adult 
Prevalence 
Deaths 
due to 
AIDS 
 
Sub-Saharan Africa 25.8 million (70%) 1.4 million 4.8% 790 000 
 
Middle East and North Africa 240 000 (<1%) 22 000 0.1% 12 000 
 
Asia and the Pacific 5.0 million (14%) 340 000 0.2% 240 000 
 
Latin America 1.7 million (5%) 87 000 0.4% 41 000 
 
Caribbean 280 000 (<1%) 13 000 1.1% 8 800 
 
Eastern Europe 
and Central Asia 
1.5 million (4%) 140 000 0.9% 62 000  
Western and Central Europe 
and North America 
2.4 million (7%) 85 000 0.3% 26 000  
Global Total 
36.9 million 
(100%) 2.0 million 0.8% 1.2 million  
Table 1. Global HIV statistics 2014, adapted from UNAIDS [91]. 
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2.11 HIV IN SWEDEN 
2.11.1 The epidemic 
In Sweden the first patient with AIDS was diagnosed in 1982 [92]. In retrospective analysis 
however, samples stored from a hepatitis A outbreak in MSM in Stockholm in 1979-80, have 
been found positive for HIV indicating the start of the Swedish epidemic [93]. Additionally, 
also in retrospective analysis, one hospitalized patient from a highly endemic country, 
returning home after release from hospital, was found to have been HIV-1 infected already in 
1976 (Sönnerborg, personal communication). 
Since diagnostics became available in 1985 there has been a mandatory case reporting of HIV 
and AIDS, regulated in the Swedish Communicable Disease Act [94]. These reports and the 
personal identity number, assigned to all Swedish citizens, have allowed for a good 
surveillance of the epidemic. However, the usage of a non-unique code, have involved some 
difficulties, particularly with the risk of duplicates. Today >99% of patients in Sweden are 
additionally registered in the national HIV Cohort, the InfCare HIV, which is equally a 
clinical support decision tool, a national quality register and a research database, assuring a 
very high quality standard of data (for further info see 5.1.2.2). 
After an initial peak of cases in the mid 80s, as a natural consequence of the possibility to test 
for HIV, the notified incidence dropped markedly and remained around 250 cases yearly until 
the 2000s, where after there has been an increase and around 400-450 cases yearly. The 
number of AIDS cases increased constantly until 1996, but has then decreased, as a result of 
ART. Whereas most patients affected in the beginning of the epidemic were MSM, soon 
followed by PWID, the majority of new diagnoses since the 90s have been made in migrants, 
primarily from high prevalence countries, reported to have been infected already before 
arrival.  
At present there are 6963 patients followed at Swedish clinics corresponding to a prevalence 
of 0.7/1000 inhabitants (Inf Care 2015-12-31). Altogether 11 247 patients have been reported 
to be HIV infected, out of which approximately 2600 have a reported AIDS-diagnosis and 
approximately 2400 are deceased (Public Health Agency of Sweden 2014-12-31).  
 
2.11.2 Demography 
The majority of PLWH in Sweden today are male, just above 60%. About half of the patients 
are infected heterosexually and one third bi/homo-sexually. 6% are infected through 
intravenous drug use. Just above half of the patients live in one of Sweden’s three major 
cities; the vast majority in Stockholm. Around 40% are born in Sweden, followed by one 
third from SSA (mainly Eritrea, Ethiopia, Uganda, Somalia, Burundi and Kenya), 10% from 
Asia/Pacific (mainly Thailand), 7% from Western Europe/North America, 4% respectively 
from East Europe/Central Asia and The Caribbean/Latin America and 2% from North 
Africa/Middle East (data obtained from InfCare HIV database). As a comparison around 
15% of the total Swedish population are born abroad [95].  
While the reported domestic infections have remained fairly constant over the years the 
variation in incidence has mainly been attributable to variations in migration patterns. The 
last years the number of reported domestic infections has slightly decreased. (Figure 5a-b). 
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An important explanation for this is the high proportion of patients on ART, but most likely, 
to some extent, also the development of needle exchange programs for PWID. However a 
risk of underestimating the number of migrants infected after arrival has been reported and 
needs to be further assessed [96]. 
 
Figure 5a. Newly reported HIV cases in Sweden, 2005–2014, divided by infected in Sweden and 
abroad. (Data provided by Maria Axelsson, Public Health Agency of Sweden).  
 
 
Figure 5b. Newly reported HIV cases in Sweden infected in Sweden, 2005–2014, divided by route 
of transmission. (Data provided by Maria Axelsson, Public Health Agency of Sweden).  
 
2.11.3 Testing, treatment and care 
Free and anonymous HIV-testing and care have been available throughout the epidemic and 
since 2004/2005 also free ART was made available by the law of communicable diseases.  
 
2.11.3.1 Testing 
Diagnosis is made primarily at STI clinics, Infectious Disease Clinics and by general 
practitioners, which contribute with around 30, 20 and 10% respectively. Around 6% are 
diagnosed through migrants’ health and 4% through maternal clinics. Approximately 10% are 
diagnosed abroad (Public Health Agency of Sweden, personal communication). 
For migrants, from countries with a high prevalence of HIV, an offer of HIV-testing was 
stated as a prioritized task by The Swedish National Board of Health and Welfare already in 
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1988. From 2008 the county councils are obliged by law to offer health examinations, 
including an opt-out offer to test for HIV, to all asylum seekers (Lag om hälso- och 
sjukvård åt asylsökande m fl. SFS nr: 2008:344 (2008-05-22). Additionally, there is the 
“National strategy against HIV and AIDS” (Proposition 2005/06:60), including the aim to 
identify possible HIV infection among all asylum seekers and newly arrived family 
connections within two months after arrival to Sweden. To what extent this has been 
obeyed was at the initiation of these studies unknown.  
 
2.11.3.2 Treatment and the continuum of care 
Diagnosed patients are treated and followed at Infectious Disease Clinics and one STI clinic. 
Altogether there are 30 specialized clinics distributed all over the country. More than half of 
the patients (55%) are treated at in total four clinics, in the three largest cities, Stockholm, 
Gothenburg and Malmö. 17% of the patients are treated at the Karolinska University 
Hospital. The care and treatment are multi-professional and involves physicians, nurses and 
as well as counsellors. If needed there are also psychiatrists, specialist in addiction medicine 
and maternal health with close collaboration with the team. 
Treatment is considered to all patients, disregarding the CD4+ T-cell count, and initiated as 
soon as the patient is prepared for this. The patients are normally monitored 2-3 times per 
year, where the HIV RNA Viral Load (VL) is the single most important marker for treatment 
success. Additionally, the CD4+ T-cell count and regular blood chemistry are followed.  
There is access to all treatment regimens, approved by the Swedish Medical Products 
Agency, and well established national recommendations on what treatment regimens to use, 
also including health economical aspects [97]. Care is primarily patient-centred and treatment 
always individualized.  
Thanks to the well-developed surveillance system, described above, the linkage from testing 
sites to HIV Care is no major problem and a recent analysis, based on the InfCare HIV, 
showed that as many as 99.8% of all individuals diagnosed with HIV were linked to care 
[98]. The vast majority, 95%, were receiving ART out of which 94.5% had an undetectable 
viral load. Retention in care was high with 97.3% of the patients having been in contact with 
their respective clinic the last year. Overall mortality is 1% per year, which is comparable 
with the mortality in the Swedish population as a whole [95]. 
Even though further improvements are always possible there is thus not much to be improved 
regarding linkage, ART, adherence and retention in care and Sweden has recently been 
declared to be the first country in the world to reach the UNAIDS “90-90-90” [99], with 90% 
diagnosed, out of which 90% on sustained ART and 90% of these with viral suppression [73]. 
However, the figure of 10% undiagnosed included in this report is a very rough estimate and 
there are on going studies indicating that the true number is somewhat higher (Sönnerborg, 
personal communication) and other assessments reporting figures of 10-20% (see 3.2 The 
hidden epidemic). Regardless of what the true number is, we do know that a majority of our 
patients are diagnosed at a late stage of infection and that people still develop and die from 
AIDS in Sweden today. To me, this implies that we definitively could improve the first step 
of the cascade, which is also the main focus of this thesis. 
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3 LATE HIV DIAGNOSIS – LATE PRESENTATION 
 
3.1 LATE DIAGNOSIS OF HIV-1 INFECTION 
With its detrimental effects on the health of the individual and its societal burden, in terms of 
increased risk of transmission and high costs, late diagnosis of HIV-1 infection has attracted 
more and more attention as a central problem in the HIV-1 epidemic [100-106]. In the 
absence of a vaccine and cure, the undiagnosed individuals have been described as the 
biggest challenge yet in the fight against HIV/AIDS in the Western world [48], where, as a 
comparison, a timely initiation of treatment today enable a healthy, reproductive life and a 
near to normal life span [50, 107-109].   
My interest in the late diagnosis of HIV infection started already in 2003, when I took the 
initiative to Paper I. At that time there were limited reports in the field and only a few studies 
covering the years after introduction of cART [110-113]. To manage the disease, the 
treatments and its side effects had absorbed a lot of attention and time, but with modern drugs 
and all requirements for a successful treatment fulfilled the incitements to get tested had now 
increased and patients still developing AIDS was seen as a failure.  
In 2006, ten years after the introduction of cART, the CDC started to recommend routine, 
opt-out, HIV screening in all individuals aged 13–64 presenting for care in any health care 
setting in the United States in order to enhance early diagnosis [114]. This meant offering a 
HIV-test to every patient, but with the option to deny, rather than pin pointing specific risk 
groups. The effectiveness of this kind of general testing has however been debated [115, 
116].  
In Europe key stakeholders from civil society, health care and European public health 
institutions gathered in Brussels in 2007 and formed a pan-European platform with the 
objective to improve early diagnosis and earlier care of HIV across Europe; the HIV in 
Europe initiative [117]. Ahead of this meeting information had been gathered by reviewing 
existing literature and found evidence of between 15 and 38% of all HIV cases being 
diagnosed late in Europe [100]. A large number already severely immune-compromised at 
diagnosis naturally also implied a hidden epidemic with a great number of people still not yet 
diagnosed.  
 
3.1.1 A pilot study at the Karolinska University Hospital 
In parallel with the HIV in Europe initiative, in which we also participated, we formed a 
group at Karolinska University Hospital aiming at improving early diagnosis in Sweden. In 
an early pilot study at our clinic in 2007 [118] it was shown that 34 of 82 (41%) of newly 
diagnosed patients had an advanced HIV disease (CD4+ T-cells < 200/mm3) and that 38% of 
these were diagnosed with the indicator diseases hepatitis B and C, TB or STI, without a 
HIV-test, prior to HIV diagnosis, indicating a doctor’s delay. The 1-year mortality among the 
34 was as high as 12%. 71% were migrants from outside of the Nordic countries, out of 
whom 96% were estimated to be infected before arrival to Sweden, as determined by the 
doctors interview with the patient. These findings indicated an obvious need of further 
studies. 
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3.1.2 The Late Presenter 
The definition of what is meant by “late” in the context of HIV-1 diagnosis has been diverse. 
Whereas some studies have used laboratory-based definitions, such as CD4+ T-cell counts 
below certain thresholds, others have used clinical definitions based on time to the 
development of AIDS. All of them have followed the same theme; that the diagnosis is late if 
the patients already should have commenced ART [100], but there was a need of a joint 
definition to enable comparisons. 
Based on results from the UK CHIC study and further endorsed by the two initiatives “the 
HIV in Europe initiative” and “late Presentation for HIV treatment in Europe program” a 
consensus definition was agreed upon and published in 2011 [106]. A so-called late 
presenter (LP) was defined as an HIV positive individual presenting for HIV care with 
a first CD4+ T-cell count <350 cells/mm3 or AIDS [2]. A subgroup of the individuals most 
severely immune-compromised, with CD4+ T-cell count <200 cells/mm3 or AIDS, was 
defined as advanced HIV [2]. (Figure 6). 
This was all in line with the treatment guidelines at the time, which stated that all patients 
with a CD4+ T-cell count <350/mm3 should receive ART even if asymptomatic [119]. 
Late presentation for care, per definition, includes both the problem of late diagnosis and 
poor linkage to care after HIV diagnosis. As a contrary to what has been described in other 
studies [71, 72] linkage is not a major issue in Sweden (see 2.11 HIV in Sweden) and the 
focus of my thesis are subsequently patients with a late HIV-1 diagnosis.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. The definition of a Late Presenter according to the European Consensus definition. 
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3.2 THE HIDDEN EPIDEMIC – ESTIMATING THE PROPORTION 
UNDIAGNOSED 
Globally, as mentioned, estimates from the UNAIDS, suggest that almost half of all PLWH 
still remain to be diagnosed [83]. In the WHO Europe region there are estimates of 30-50% 
undiagnosed [120], with proportions ranging from 12-20% in Scandinavia to just above 50-
60% in some Eastern European countries and Russia [99, 120, 121]. Numbers reported from 
the US are similar to those in Western Europe, with up to one-quarter of the HIV positives 
undiagnosed [122]. Rough estimations from Sweden have reported numbers of 10-20%. 
These have been based on the prevalence of patients with simultaneous HIV and AIDS-
diagnosis (10-12%), a low prevalence of non-diagnosed HIV in maternal and blood donor 
screening (1/10 000) and a large proportion of migrants among the late diagnosed, expected 
to have spent most of their time unaware of their diagnosis abroad [123].  
To get accurate estimates of the size of the HIV epidemic is important to facilitate plans for 
HIV-testing and the corresponding treatment and also to evaluate national prevention and 
treatment programs. There are several ways to do this, historically most commonly by using 
prevalence surveys [124]. There are also methods based on estimations of cumulative 
incidence of HIV infections [125-129] and those based on surveillance of simultaneous 
HIV/AIDS cases, like the London method [130]. 
To be able to make as good estimations as possible it is recommended to collect data on HIV 
diagnosis, CD4+ T-cell count at diagnosis, proportion with simultaneous HIV/AIDS and 
data on deaths in people with HIV [124]. 
Many of the models have required quite advanced modelling, but recently the ECDC 
published a tool, based on the Incidence method and the London method, of simultaneous 
HIV/AIDS cases, that is possible for anyone to download as a desktop application 
(http://ecdc.europa.eu/en/healthtopics/aids/Pages/hiv-modelling-tool.aspx). By introduction 
of basic surveillance data to these, estimates of both the proportion not yet diagnosed and the 
average time between infection and diagnosis can be received. 
While above-mentioned methods all are based on surveillance data there are also models 
based on serological assays, such as the BED-test (HIV-1 IgG capture BED enzyme-linked 
immunoassay) with which the HIV incidence can be calculated by detecting seroconversions 
as a sign of recent infection (approximately within six months) [131, 132]. Additional 
algorithms, such as the RITA (recent infection testing algorithm) [132, 133], use the BED-
test together with the CD4+ T-cell count and clinical information, like on going ART, 
and/or an AIDS-defining illness taken into account [132]. 
All methods produce valuable, but rough estimates and refined tools would make a valuable 
contribution in estimating the true proportion of persons living with an undiagnosed HIV 
infection. Important prerequisites are naturally the country involvement and national 
surveillance systems that are operating satisfactory. 
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3.3 CONSEQUENCES OF THE LATE DIAGNOSIS 
3.3.1 Increase in mortality and morbidity 
3.3.1.1 Mortality 
Late presentation of HIV-1 infection is associated with severe and sometimes fatal 
consequences for the individual and in regions with full access to ART, a delay in diagnosis 
is now being a dominating reason for HIV related death [3, 134-136]. In total late diagnosis 
has been described to account for one third of all HIV related deaths and as much as one 
quarter of all deaths in HIV positive individuals in a western country [100]. Most of the 
deaths in HIV-1 patients occur within the first year after diagnosis and over 90%, of this 
short-term mortality, can be related to a late diagnosis per se. Comparing the mortality in 
the newly diagnosed LP with those diagnosed early there is at least a 10-fold increased risk 
of dying within the first year (4.1% versus 0.3%) [137] and the more immunosuppressed 
naturally the higher risk [136]. 
Also long term mortality is affected and patients with a CD4+ T-cell count < 200 cells/mm3, 
when they commence ART, have been estimated to have a life expectancy, at 20 years of age, 
that is at least ten years less than that in those who initiate ART when the CD4+ T-cell count 
had just fallen below 350 [107]. Late diagnosis and treatment start at lower CD4+ T-cell 
counts are associated with a poorer immune recovery [138, 139], but if there is a significant 
raise in the CD4+ T-cell count, after starting ART, and levels >500/mm3 are reached, the 
mortality is similar to that of the general population for non-PWID. However, regardless of a 
gain in CD4+ T-cells, even above 500/mm3, an increase in mortality remains for those with a 
previous AIDS defining illness [46]. 
 
3.3.1.2 Morbidity 
Late presentation and treatment start at low CD4+ T-cells count are associated with an 
increased risk of both HIV- and non-HIV-related morbidity such as opportunistic diseases, 
AIDS- and non-AIDS-defining cancers as well as cardiovascular, hepatic and renal disease 
[3] and as such also premature aging [140]. Most likely this is due to larger latent viral 
reservoirs [141] and a higher degree of chronic inflammation [65, 66] in these patients. 
Also, patients presenting late have been proven to be more difficult to treat, since there, in 
addition to the blunted or delayed CD4 response, is an increased risk of drug-drug 
interactions, toxicity and the immune reconstitution syndrome [142].  
Even though different cut-offs of CD4+ T-cells have been discussed studies, like the SMART 
study, have indicated that there is no clear threshold, but rather a continuum of increased risk 
for both disease progression and death associated with lower CD4+ T-cell counts [143, 144]. 
In the spring 2015 the START trial also showed a clear advantage of immediate ART, 
disregarding the CD4+ T-cell count, with a significant reduction of AIDS and death in those 
starting with CD4+ T-cell counts >500/mm3 compared to those waiting until 350/mm3 [58], 
making the early diagnosis increasingly important.  
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Figure 7. Cumulative probability of (A) AIDS or death or (B) death alone after initiation of 
combination antiretroviral therapy, according to range of CD4 cell count at the time of treatment 
initiation. JA Sterne et al, Lancet 2009 [145]. 
 
3.3.2 The risk of onward transmission 
Since the average time from HIV infection to symptomatic disease is as long as 8-10 years, 
without treatment [44], there are several years when an undiagnosed carrier accidently, and 
completely unaware, could be transmitting the virus to others, most prominent at PHI and at 
the late stages of infection [146, 147]. Estimations show that in an HIV population, where 
25% are unaware of their infection, these count for 54% of all new transmissions, 
corresponding to a 3.5 times higher likelihood to transmit the virus [4]. 
Awareness of HIV-infection is per se associated with modified sexual behaviours [148-151], 
but most important for the reduced infectivity of HIV is the use of ART, which reduces a 
person’s infectiousness by reducing plasma and genital HIV viral loads [152, 153]. One of 
the earliest and best documented proofs of this is the dramatic reduction seen in mother-to-
child transmission, where in Europe the risk of vertical transmission has decreased from 
15.5% in 1994 [104] to virtually zero in those well treated today [154]. 
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As for sexual transmission scientific data unambiguously show that ART substantially 
reduces the contagiousness of HIV, as well at a population [155] as at an individual level, 
where the landmark study, HPTN 052, showed a 96% risk reduction of transmissions in 
heterosexual serodiscordant couples, when the HIV-positive partner received ART [156]. 
Also the ongoing Partner study, reports no transmissions after nearly 890 couple years of 
follow up in 586 heterosexual and 308 MSM serodiscordant well treated couples [157], 
presenting the first evidence of a risk reduction also for MSM. Even though it is scientifically 
still not possible to state a null-risk and longer follow up is needed; as it is stated in the 
“Swiss statement” [152], many experts now consider a HIV positive individual, with 
undetectable viral load for at least 6 months and without other sexual transmitted diseases 
(STIs) to have minimal contagiousness [35]. 
During recent years there have been a lot of discussions about treatment as prevention (TasP) 
and the “test and treat” strategy aiming at eliminating the HIV epidemic by annual universal 
testing followed by immediate ART if diagnosed positive [158]. Even though this does not 
seem realistic in the short term, early diagnosis and ART, in the absence of a protective 
vaccine, is the most promising strategy to control the pandemic. 
 
3.3.3 Health economical aspects 
At a societal level late presentation is associated with a direct and indirect burden on health 
economy [159]. 
Whereas the total cost is hard to assess, there are reports of the direct medical cost. One large 
US study demonstrated the later to be significantly higher in late presenters compared to 
those initiating treatment with a CD4 > 350 and remaining twice as high the subsequent years 
despite significantly improved CD4 [159]. Additionally, another US study also demonstrated 
higher direct medical costs continuing even after 7 to 8 years in care [160].  
One should also keep in mind the cost before the diagnosis of the patient where many patients 
are the subjects of comprehensive, often unnecessary and sometimes also invasive 
investigations before someone even think of HIV [161]. 
 
 
3.4 WHO ARE THE LATE PRESENTERS? 
The characteristics of Late Presenters differ in different regions of the world, in different 
countries and even in different cities and settings and late presentation has been observed to 
be common in all demographic groups [162]. However some main common features have 
been identified; Late presenters tend to be those who do not perceive themselves, or are not 
perceived to be, at risk of HIV infection, those who are not routinely offered HIV testing, and 
are often from marginalized groups [104]. 
At the initiation of my study some studies had also identified an association with older age 
[110, 163] and foreign birth [110, 163, 164] as risk indicators for late diagnosis, whereas 
results regarding gender and transmission groups had been conflicting [162].  
The situation in Sweden was at the time not known and studies assessing this needed. 
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3.5 MISSED OPPORTUNITIES FOR TESTING  
With a latency phase of several asymptomatic years before getting ill [44] it is understandable 
that many HIV infected patients do not seek health care until late stages of their infection. 
However several individuals do seek health care facilities for HIV associated conditions, so 
called indicator diseases [165], both during a symptomatic primary infection and later on, 
without getting tested for HIV [166-169]. People also attend health care services for different 
reasons, when an epidemiological risk factor could indicate that a HIV-test would be 
adequate, disregarding the reason for the medical contact.  
In addition to this there are the political challenges related to immigration, where the practice 
to perform health examinations, including HIV test, often are inadequate. Finally, there is 
also the delay of the patient in seeking health care.  
All the above represent missed opportunities for testing and consequently also missed 
opportunities for treatment and prevention. 
One of the main aims with this thesis was to assess the extent of missed opportunities in a 
Swedish context. 
 
 
3.6 INDICATOR GUIDED TESTING 
As a contrary to the general opt-out HIV testing, proposed by the CDC in the US [114], 
most countries in Europe, through the initiative HIV in Europe [117], have favoured a 
strategy of targeted testing. Since the historically predominant strategy, based on risk 
factors, have failed to identify a substantial proportion of PLWH, focus is now aimed at 
identifying any patient presenting with conditions that could be indicative of HIV, 
irrespective of previous risk assessments [165]. These conditions include: 
 
• All conditions that would be AIDS-defining in PLWH 
• Other HIV associated conditions 
• Conditions not associated to HIV, but where HIV is important to rule out to prevent 
future complications in the clinical management of the patient. 
 
The first and the last (including mainly conditions needed to be treated with different kind of 
immunosuppressive therapy) are rather straightforward whereas the HIV associated 
conditions could be many and are less well defined. These include infections that share a 
common mode of transmission with HIV (e.g. hepatitis, sexually transmitted infections 
(STI)), diseases who are favoured by the immunodeficiency induced by HIV (e.g. oral thrush, 
zoster (VZV)) and any other medical condition associated with an untreated HIV infection 
(e.g. fever of unknown origin, blood dyscrasia). For a more detailed list on indicator 
conditions, see Table 2 on page 26-27. 
In health economic studies from France and the US cost effectiveness of general screening 
have been demonstrated at an undiagnosed HIV prevalence of 0.1 % [170, 171], in one study 
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as low as 0.05% [172]. The prior has been used as a rule of thumb of when it is indicated to 
screen for HIV and utilized for the HIV associated conditions, but also to decide on when 
screening is indicated within targeted groups and in the general population. For example in 
the UK HIV testing is recommended by GPs in all newly registered individuals 15-59 years 
in areas with a diagnosed HIV prevalence >/=2 /1000 inhabitants [173]. 
 
 
3.7 BARRIERS TO HIV TESTING 
Barriers to testing are several, but my personal clinical experience is that a patient very 
seldom says no when getting an offer to test. This has also been confirmed in studies, where 
the patient acceptability has been >90% and a low testing rate rather have been due to staff 
generated barriers [166, 174].  Barriers among health care professionals have been described 
to include lack of education and self confidence [175], discomfort [176], concerns about the 
consent process and competing priorities [177, 178], but also failure in risk assessments 
[179]. For the patients well-known barriers include low risk perception of HIV infection, 
structural barriers, fears of the disease or of negative consequences, such as HIV-related 
stigma and concerns about confidentiality [175, 180].  
Patient’s barriers to HIV testing are being assessed by our research team but are not within 
the scope of this thesis. 
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Table 2. Indicator conditions for HIV infection and specialties involved.  
Adapted from Lazarus et al. HIV Med 2013 [165]. 
1. Dentistry  
• Oral hairy leukoplakia2 
• Candidiasis, oral and oesophageal1* 
• Kaposi’s sarcoma1* 
2. Dermatology/dermatovenereology/genitourinary medicine 
• Kaposi’s sarcoma1* 
• Herpes simplex ulcer(s)1* 
• Atypical disseminated leishmaniasis1* 
• Penicilliosis, disseminated1* 
• Seborrheic dermatitis/exanthema2* 
• Herpes zoster2* 
• Sexually transmitted infections2* 
• Hepatitis B or C (acute or chronic) 2* 
• Severe or recalcitrant psoriasis2 
• Candidaemia2 
• Candidiasis2 
3. Gastroenterology/hepatology  
• Cryptosporidiosis diarrhoea, >1 month1* 
• Microsporidiosis, >1 month1* 
• Isosporiasis, >1 month1* 
• Candidiasis, oesophageal1* 
• Hepatitis B or C (acute or chronic) 2* 
• Unexplained chronic diarrhoea2** 
4. Gynaecology/obstetrics  
• Cervical cancer1* 
• Sexually transmitted infections2* 
• Hepatitis B or C (acute or chronic) 2* 
• Pregnancy (implications for the unborn child) 2 
• Cervical dysplasia2* 
5. Haematology  
• Lymphoma, non-Hodgkin1* 
• Malignant lymphoma2 
• Unexplained leukocytopenia/thrombocytopenia lasting >4 weeks2* 
• Thrombotic thrombocytopenic purpura3 
6. Infectious diseases/internal medicine  
• Tuberculosis1* 
• Mycobacterium tuberculosis, pulmonary or extrapulmunary1* 
• Mycobacterium avium complex (MAC) or Mycobacterium kansasii, disseminated or 
extrapulmonary1* 
• Mycobacterium, other species or unidentified species, disseminated or extrapulmunary1* 
• Pneumonia, recurrent (two or more episodes in 12 months) 1* 
• Pneumocystis jirovecii pneumonia1* 
• Cryptococcosis, extrapulmonary1* 
• Salmonella septicaemia1* 
• Cytomegalovirus, other (except liver, spleen or glands) 1* 
• Herpes simplex ulcer(s) >1 month with bronchitis/pneumonitis1* 
• Candidiasis bronchial/tracheal/pulmonary1* 
• Candidiasis, oesophageal1* 
• Histoplasmosis, disseminated/extrapulmonary1* 
• Coccidiodomycosis, disseminated/extrapulmonary1* 
• Atypical disseminated leishmaniasis1* 
• Reactivation of American trypanosomiasis (meningoencephalitis or myocarditis) 1* 
• Penicilliosis, disseminated1* 
• Sexually transmitted infection2* 
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• Hepatitis B or C (acute or chronic) 2* 
• Mononucleosis-like illness2* 
• Invasive pneumococcal disease2 
• Herpes zoster2* 
• Lymphocytic meningitis2 
• Visceral leishmaniasis2 
• Unexplained weight loss2** 
• Unexplained fever2* 
• Unexplained chronic diarrhoea2** 
• Unexplained lymphadenopathy2* 
• Unexplained leukocytopenia/thrombocytopenia lasting >4 weeks2* 
7. Nephrology  
• Unexplained chronic renal impairment2 
8. Neurology and neurosurgery  
• Cerebral toxoplasmosis1* 
• Cryptococcosis, extrapulmonary1* 
• Progressive multifocal leucoencephalopathy1* 
• Reactivation of American trypanosomiasis (meningoencephalitis or myocarditis)1* 
• Guillain–Barré syndrome2 
• Mononeuritis2 
• Subcortical dementia2 
• Multiple sclerosis-like disease2 
• Peripheral neuropathy2 
• Primary space-occupying lesion of the brain3 
9. Oncology  
• Lymphoma, non-Hodgkin1* 
• Kaposi’s sarcoma1* 
• Primary lung cancer2 
• Anal cancer/dysplasia2* 
• Cancer requiring aggressive immunosuppressive therapy3 
10. Ophthalmology  
• Cytomegalovirus retinitis1* 
11. Otorhinolaryngology  
• Candidiasis tracheal/oesophageal1* 
• Mononucleosis-like illness2* 
12. Rheumatology  
• Autoimmune disease treated with aggressive immunosuppressive therapy3 
13. Respiratory medicine/pulmonology  
• Tuberculosis1* 
• Pneumocystis jirovecii pneumonia1* 
• Pneumonia, recurrent1* 
• Mycobacterium avium complex (MAC) lung disease1* 
• Histoplasmosis, disseminated/extrapulmonary1* 
• Herpes simplex bronchitis/pneumonitis1* 
• Candidiasis bronchial/pulmonary1* 
• Community-acquired pneumonia2 
14. Emergency medicine  
• Symptomatology fitting any of the listed conditions 
13. General practice  
• Symptomatology fitting any of the listed conditions 
1 AIDS-defining conditions among people living with HIV 2 Conditions associated (or likely to be associated) 
with an undiagnosed HIV prevalence of >0.1% 3 Conditions where not identifying the presence of HIV infection 
may have significant adverse implications for the individual’s clinical management despite the estimated 
prevalence of HIV being likely to be < 0.1%. *Assessed in paper II-III (** only if consistent with wasting). 
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4 AIMS 
 
The overall aim of my thesis was to assess key aspects related to late diagnosis and missed 
opportunities for timely diagnosis and care in the Swedish HIV-1 epidemic. 
 
The specific aims were: 
Paper I 
§ To analyse the characteristics of patients who were unaware of their HIV-1 infection 
until they developed AIDS, in the period after introduction of highly active 
antiretroviral therapy. 
§ To test the hypothesis that the proportion of patients with late HIV-1 diagnosis was 
increasing. 
 
Paper II 
§ To assess the prevalence of Late Presenters of HIV-1 infection in Sweden, according 
to the new European consensus definition [2]. 
§ To identify factors in the newly diagnosed HIV-1 infected patients and within the 
health care system, which contribute to late diagnosis. 
 
Paper III 
§ To further characterize and identify risk factors for the missed opportunities of HIV-1 
diagnosis identified in Paper II.  
 
Paper IV 
§ To assess whether the number of migrants infected after arrival to Sweden is 
underestimated, by comparing the estimates of the country of HIV-1 acquisition using 
a CD4+ T-cell decline trajectory model with what was clinically reported. 
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5 MATERIAL AND METHODS 
 
5.1 STUDY POPULATION AND DATA COLLECTION 
All studies in my thesis were conducted in Sweden, a country with nearly 9.8 million 
inhabitants and an HIV-prevalence around 0.7/1000 inhabitants. For further details about the 
study setting, see Background; 2.11 HIV in Sweden. 
 
5.1.1 Study population  
In Paper I, the national register of HIV and AIDS at the Public Health Agency of Sweden 
(former Swedish Institute for Infectious Disease Control) (see 5.1.2.1) was used to select all 
patients ≥15 years old registered with an AIDS diagnosis in Sweden between 1996 and 
2002. 
The year 1996 was chosen in order to study the HAART era. All children under the age of 
15 were excluded since AIDS development in a child rather could be attributed to factors 
relating to the parents than to the child per se.  
For Paper II-III, all the four largest HIV clinics in Sweden, located in the three major cities 
(Stockholm, Gothenburg, and Malmö) and additional county clinics, with which the research 
team had an established collaboration, were approached and invited to participate. In total 12 
clinics, distributed all over the country and representing 75% of the national HIV care, joined 
the study.  
For every clinic a designated principal investigator was chosen. Together with the research 
team three of these formed a steering committee that had the possibility to give input on the 
study design before this was finalized. 
At the 12 clinics all patients, ≥18 years, who were newly diagnosed with HIV-1, from 1st of 
October 2009 to 31st of January 2012, were included in the study. Within six months the 
patients were asked to participate in a sub-study based on a more detailed questionnaire. 
 
 
 
 
 
Figure 8. Flowchart of 
the patients included in 
the Paper II-III study 1st 
of October 2009 to 31st of 
January 2012. 
 
All new patients registered 
in InfCare HIV 
(n=827) 
All new patients at the 12 
study clinics 
n=638 (77%) 
 
All patients previously not 
known to be HIV (+)    
(=newly diagnosed) 
n=575 (90%) 
 
Patients participating in the 
questionairre 
n=409 (71%) 
Patients in the study 
cohort, not participating in 
the questionairre  
n=166 (29%) 
New patients with an 
already known HIV 
diagnosis (> 6 months) 
n=63 (10%) 
All new patients at non 
study clinics 
n=189 (23%) 
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In Paper IV all non-Swedish born individuals (all defined as migrants), aged 15 or above, 
with an HIV-1 diagnosis between 1983 and 2013, with a known year of arrival and without a 
known PHI or mother to child transmission (MTCT), registered in the InfCare HIV (see 
5.1.2.2 below), were included. In a sub-study, made for sensitivity analysis, we excluded all 
patients resident less than six months in Sweden at diagnosis.  
 
5.1.2 Sources of data 
5.1.2.1 The national register of HIV and AIDS  
In Sweden there has been a mandatory case reporting of HIV since 1983 and during the 
period 1985-2005 also of AIDS (National Health Protective Agency, yearly report 2014). 
The cases are reported, by a non-unique patient code, to the local County Medical Officer 
and to the Public Health Agency of Sweden, former Department of Epidemiology at the 
Swedish Institute for Infectious Disease Control (EPI/SMI), where they are registered in a 
national register of HIV and AIDS. This register was used in Paper I. 
At the time of the study a complementary questionnaire, collecting additional and missing 
information about the patient was sent to the patient’s physician six months after the initial 
case report, and subsequently entered into the same database. This information further 
helped in the cleaning process of the register and minimized the possibility of remaining 
duplicates. 
5.1.2.2 The InfCare HIV 
The InfCare HIV, used in Paper II-IV, was initiated in 2003 and incorporates >99% of all 
HIV-1 infected patients living in Sweden today and an additional high proportion of deceased 
individuals, with diagnosis from 1983 and onwards. It is equally as a research database, a 
national quality register for the Swedish HIV Care and a day-to-day electronic decision 
support tool in the clinic (Figure 9), where all patients are followed from diagnosis and 
onwards.  
It contains socio-demographic data (gender, age, country of origin, estimated country of 
transmission, route of transmission, date of first positive HIV serology) and biological data 
(CD4+ T-cell count, plasma and CSF HIV RNA, HCV and HBV serostatus), ART history 
and data on HIV drug resistance, including the viral sequences.  
Whereas assigned medical staff registers personal data, the majority of the biomedical 
parameters are retrieved electronically, in real time (once a night), from the laboratory, 
making the database continuously up to date and of very good quality. Internal validation is 
assured through a quality index and external evaluations have been performed by IBM 
Research Haifa, the Mac Planck Institute of Bioinformatics and through the Cohere database 
quality assurance system (HIV Cohorts Data Exchange Protocol) (http://www.eurocoord.net).  
As of 31st of December 2015 there were 10,437 patients registered in the database and 6,969 
patients followed at the Swedish clinics. 
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Figure 9. Patient graph from the decision tool in InfCare HIV 
5.1.2.3 Questionnaire 
For Papers II-III an in-house questionnaire was developed. The questions were based on an 
extensive literature review on late HIV diagnosis including psychosocial aspects of living 
with HIV as well as the involvement of experts in the area of infectious diseases, addiction 
medicine, public health, epidemiology and community representatives. The feasibility of the 
items was assessed through interviews with people living with HIV, in collaboration with the 
patient-organisation HIV-Sverige (former Riksförbundet för hivpositiva). 
The questionnaire was completed by the treating physician and based on the medical history 
from the patient and on hospital journals, for those patients who agreed to participate in the 
sub-study. An interpreter participated if necessary. Part of the data collected was also used in 
Paper IV. For details on the data collected and used see 5.4.1 Variables below. 
 
 
5.2 THE CD4+ T-CELL DECLINE TRAJECTORY MODEL 
The method for assigning probable country of HIV acquisition among migrants was first 
developed by Public Health England, in collaboration with the European Centre for Disease 
Prevention and Control (ECDC) in 2012 [96] and later revised and improved including 
collaboration with our research group (In manuscript: “Probable country of HIV infection 
acquisition among diagnosed people born outside a country: applying a new method on four 
European countries”). In summary, the method, which is based on factors associated with the 
intercept and the slope of CD4+ T-cell decline in a large group of seroconverters, uses a 
mathematical algorithm to model CD4+ T-cell decline trajectories in ART naïve patients in 
order to estimate their time from HIV seroconversion. Since the CD4+ T-cell count at 
infection varies significantly by ethnicity and the rate of CD4+ T-cell cell decline is 
associated both with ethnicity and age [96, 181, 182], these demographic variables were kept 
 32 
in the model and adjusted for. The algorithm also considered the variability of CD4+ T-cell 
count at PHI [43], by excluding all CD4+ T-cell counts within the first three months.  
If the estimated period of seroconversion was after the calendar year of arrival, the patient 
was categorized as having acquired HIV in Sweden and likewise outside Sweden if the 
estimate of seroconversion was prior to year of arrival. Patients for which the year of arrival 
was within the time estimate of seroconversion were instead categorized as uncertain. 
These estimates were then compared with the doctor’s estimate, registered as country of 
HIV-1 transmission in InfCare HIV. 
 
 
5.3 PHYLOGENETIC ANALYSIS 
Whereas the CD4+ T-cell model, described above, is a public health tool that was developed 
to make estimates on the population level, phylogenetic analysis could be used on the 
individual level to determine the source of incident cases and possible transmission clusters 
[183]. 
In the Swedish HIV treatment guidelines sequencing of the HIV-1 pol gene is recommended 
routinely to identify any transmitted drug resistance. The sequences are transferred 
electronically and registered in the InfCare HIV database [28]. Using these sequences, a 
phylogenetic analysis was performed anonymously without having details on patients’ 
demographics, partner history or migration history. An anonymised maximum likelihood 
phylogenetic tree with the general time reversible (GTR) with inverse gamma (GTR+G+I) 
model was conducted on main five HIV-1 subtypes (A1, B, C, 01_AE, 02_AG) for which 
>50 sequences were available (n=863). Sequences with complete protease (aa 1-99) and 
partial reverse transcriptase (aa 1-300) were only used after excluding known drug resistant 
mutation positions. “Discordant” samples of these five subtypes (n=71) were labelled as 
infected in “Sweden” or “outside Sweden” based on it’s clustering with “concordant” (both 
model and doctor) sequences with >70% bootstrap support (BS). A singlet sequence or 
sequence clustering with other sequences with <70% BS, the sequences were termed as 
“Uncertain”.  
 
 
5.4  VARIABLES AND OUTCOME DEFINITIONS 
5.4.1 Variables 
In Paper I, variables collected from the national register of HIV and AIDS were sex, age, 
reported country of origin, country and route of transmission and date of HIV-and AIDS-
diagnosis, respectively. The AIDS-diagnosis used in Sweden is the one based on the 1993 
Expanded European AIDS case definition [184] and holds for all papers, I-IV. 
In Papers II-IV, gender, age, reported country of origin, country and route of transmission, 
CD4+ T-cell counts, date of first positive HIV test and any AIDS diagnosis were collected 
from InfCare HIV. For migrants also the year of arrival (immigration date) were collected, 
when available. 
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In Papers II-III information on missed AIDS- [45] or HIV-associated symptoms or such 
symptoms neglected by the patient (appearing within the preceding three years), psychiatric 
illness, substance use, immigration date, health examination including HIV-test at 
immigration, the initiator of the HIV-test and the reason for testing was collected from the 
questionnaires. (For details on the missed HIV-associated conditions please see appendix, 
Paper II-III). The questionnaire data regarding origin and immigration date was also used for 
Paper IV. 
For Papers II-III, the countries of origin and transmission were grouped into regions based 
on the Joint United Nations Program on HIV and AIDS (UNAIDS) [185] definitions for 
descriptive analysis, and further grouped into: Sweden; the East (East Europe/Asia/Pacific); 
sub-Saharan Africa (SSA); Other (Western Europe, North and Latin America, Caribbean, 
North Africa, Israel, Middle East) and Unknown for inferential analysis. For Paper IV the 
countries of origin were grouped into world region of birth: Africa; Europe and Other 
whereas the country of transmission (doctor´s estimate) was dichotomized as Sweden or 
outside Sweden. The country of transmission estimated by the CD4+ T-cell algorithm was 
categorized as Sweden, outside Sweden and uncertain, as specified above. 
For patients born outside Sweden a missed opportunity to test at immigration was defined as 
immigration date ≥1st of January 1988 and HIV diagnosis >two months after immigration, if 
not tested negative at immigration. The reason for choosing 1988 was the recommendations 
from the Swedish National Board of Health and Welfare including offering of testing as a 
prioritized task to refugees from countries with a high prevalence of HIV that year. 
  
5.4.1 Outcomes 
In Paper I the outcome was late tester, defined as a patient with AIDS, for whom the time 
interval between first positive HIV test and AIDS diagnosis was < 3 months. This time 
interval was chosen since it had been used in previous studies [111], but mainly because it 
was regarded long enough to cover any possible delay in AIDS-diagnosis after the 
diagnosis of HIV. All patients with 3 or more months between HIV and AIDS diagnosis 
were defined as non-late testers. 
In Paper II the main outcome was late presentation (LP) defined on the basis of the 
European consensus definition [2]; CD4 <350 cells/mm3 or AIDS (within three months of 
diagnosis). As an amendment to the definition we choose to include also PHI and defined all 
patients with CD4 <350 cells/mm3, who had laboratory results and/or medical history 
confirming PHI the previous year as a non-late presenter (nLP). The LP were further 
subdivided into: LP without advanced HIV disease (LPnAH): CD4 200–349 cells/mm3 and 
no AIDS and LP with advanced HIV disease (LPAH): CD4 <200 cells/mm3 or AIDS. 
(Figure 10). The CD4 count closest to diagnosis was the one used. Since we allowed for the 
patients to be included within 6 months, this was also the time span defined for the CD4, 
presumed the patient had not yet started ART. 
In Paper III primary outcomes were two different kinds of missed opportunities of HIV 
testing, already described in paper II; Missed at presentation, defined as a failure to diagnose 
a clinical indicator for HIV testing within the national medical service the three years 
previous to the diagnosis and Symptoms neglected by the patient, defined as the presence of 
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any HIV or AIDS associated symptom, experienced by the patient, without seeking medical 
care, at all or not until additional symptoms evolved, the three years previous to the diagnosis. 
Secondary outcome was the initiator of the test. 
In Paper IV a variable, having as categories all the possible combinations of disagreement 
between the doctor and algorithm estimates, called discrepancy was created and further 
dichotomized in two groups, according to if the doctors and the algorithm agreed or not.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10. The adjusted definition of the Late Presenter used in paper II-III. 
 
 
 
5.5 STATISTICAL ANALYSIS 
In all papers data was summarized with descriptive statistics (mean, median, standard 
deviation for numerical variables, frequencies and percentages for categorical variables).  
In the bivariate analysis cross tabulations with Chi-Square or, when numbers were small, 
Fisher test were used to test for un-adjusted relationship between categorical outcomes and 
categorical independent variables. For numerical outcomes, t-test or Wilcoxon rank sum test, 
and ANOVA or Kruskal Wallis test were used to compare mean and medians in two and 
more groups respectively. 
For the multivariable analysis, adjusting for confounders, a binary (for binary outcomes) 
and a multinomial (for categorical outcomes with more then two categories) logistic 
regression model were used to identify predictors in Paper II. In Paper III we used the 
binary logistic regression whereas again, the multinomial logistic regression model was used 
in Paper IV.  
Crude and adjusted odds ratios (OR) with 95% confidence intervals were presented. P-values 
<0.05 were considered significant in the final models.  
CD4≥350 
 
           CD4<350 
 
CD4<200 
or  
AIDS 
 
Non-Late Presenter (nLP) 
Late Presenter (LP) 
Late Presenter with Advanced HIV (LPAH) 
AIDS 
 
PHI 
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Additionally, in order to study nonlinear associations among migrants infected abroad, in 
relation to number of months in Sweden, with probability of being late and type of test 
initiator, generalized logistic models were used, fitting restricted cubic splines for months in 
Sweden, choosing four knots according to Harrell's recommended percentiles, in Paper III.  
Data analysis was done using the STATA software 13 (Stata Corp. College Station, USA). 
 
 
5.6 ETHICAL CONSIDERATIONS 
All four studies were conducted in accordance to the declaration of Helsinki [186] and 
approved by the Regional ethics committee in Stockholm (Diary number 03-170, 2009/1029-
31/1-4 and 2014/928-31/2) and by the Regional ethics committee in Gothenburg (Diary 
number 532-11 including amendment 20111118). 
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6 RESULTS AND DISCUSSION 
 
6.1 PAPER I 
6.1.1 Late testers in Sweden 1996-2002 
A total of 487 patients, ≥ 15 years, reported with AIDS in Sweden 1996-2002 were identified, 
of whom 219 (45%) were late testers and thus previously unaware of their HIV-1 infection. 
The incidence of late testers was fairly constant over the study-period, but their proportion of 
patients with AIDS increased from 22% in 1996 to nearly 60% at the end of the study. 
Whereas the high proportion of patients with AIDS despite an early diagnosis (non-late 
testers) in 1996 was a natural consequence of cART just becoming available [187], there was 
still a small trend towards a higher proportion of Late Testers during the following years 
(Figure 11). Similar observations had been made in other European countries [110, 111] and 
Australia [112], with proportion of late testers ranging from 35% to the 60% seen at the end 
of our study. 
 
 
 
Figure 11. AIDS cases in Sweden 1996-
2002 divided into "late" and "non-late 
testers". Absolute numbers on Y-axis. 
 
6.1.1.1 Demography of the study-patients  
The demographic characteristics of the patients are depicted in Table 3. In summary three 
quarters of the patients were male. Median age at diagnosis was 34 (range 17-91) years. 
Heterosexual route of transmission dominated (46%), one third were MSM and 13% infected 
through IDU. The majority (58%), originated from Sweden, 23% from Africa and 9% from 
Asia (results not shown). A total of 44% were infected in Sweden, whereas 17% were born in 
Sweden and infected abroad and 35% born and infected abroad. For 3% there was no data. 
This predominance of males could to a large extent be explained by nearly half of them 
belonging to the MSM group. However male sex was still predominant among heterosexuals 
born in Sweden (75 vs 25%), whereas the proportion of women was slightly higher among 
patients born abroad and infected heterosexually (55 vs 45%). In comparison with just above 
60% males, among PLWH at present (data obtained from InfCare HIV), this reflects the 
change in the Swedish HIV-1 epidemic, which is now being dominated by heterosexually 
infected patients, born abroad. Naturally an additional explanation for the large proportion of 
males in our study-population could be an assumption that males are more likely to develop 
AIDS and thus more likely to have been included in this study. However, an analysis of the 
likelihood of an AIDS diagnosis, in our more recent cohort (paper II and III), shows no such 
association (results not shown). 
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  "Late" (%) "Non-Late" (%) P-value 
    
Absolute number 219 (45) 268 (55)      
Gender    Female 59 (27) 68 (25)  Male 160 (73) 200 (75)      
Age    <40 113 (52) 209 (78)  >40 106 (48) 59 (22) P<0.001 
    
Route of Transmission    Heterosexual 116 (53) 108 (40) P<0.01 
Men who have Sex with Men 77 (35) 89 (33)  Intravenous Drug Users 6 (3) 59 (22) P<0.001 
Blodproduct/transfusion 2 (1) 8 (3)  Unknown 18 (8) 4 (1)  
    
Origin/Place of Infection    Infected in Sweden 76 (35) 139 (52) P<0.001 
Borne in Sweden-Infected Abroad 51 (23) 33 (12) P<0.002 
Borne and Infected Abroad 79 (36) 93 (35)  Unknown 13 (6) 3 (1)   
    
 
Table 3. Characteristics of ‘late’ and ‘non-late’ testers diagnosed with AIDS in Sweden 1996–2002. 
6.1.1.2 Characteristics of the late tester 
The sex distribution among the late and non-late testers was similar, with approximately 75% 
males in both groups, on the contrary to other studies where male gender have been 
associated with a late diagnosis [110, 111].  
The proportion of patients aged above 40 years were more than twice as high among the late 
testers than the non-late (48 vs 22%, p<0.001) and age as an important factor associated was 
at the time also described by others [110, 163, 164]. Among men in the study the late testers 
were approximately ten years older than the non-late tester, with a median age of 42 and 33 
years respectively (p<0.0001), whereas there was no significant difference in women, with a 
median age of 31 years. This could be explained by the female predominance among 
migrants, whom were younger than those patients born in Sweden, but also more likely to be 
diagnosed late (see below). 
In the initial year of the study the majority of late testers were MSM, but then there was a 
shift with an increasing incidence of those heterosexually infected (Figure 12). Overall 
heterosexual route of transmission was predominant in both late and non-late testers, but 
more prevalent among the prior (53 vs 40%, p<0.01), whereas the proportion of MSM was 
similar, with approximately one third in each group. A major difference were seen for PWID, 
which constituted only 3% (6/219) of late testers compared to 22% (59/268) of the non-late 
p<0.001). A similar pattern, with increased risk for heterosexuals compared to PWID to be 
diagnosed late, was described in Italy [111], but other studies at the time showed 
conflicting results [110, 162]. Whereas this could indicate a higher perception of risk 
associated with IDU, both among patients and the caregiver, another explanation naturally 
could be a disproportionally higher prevalence of disease progression to AIDS, despite a 
known HIV diagnosis, in this group, as a result of the inferior adherence to treatment and/or 
retention in care [188]. Overall the highest proportion of late testers was seen in those with an 
unknown route of transmission, 82% (18/22). 
 38 
 
Figure 12. Late testers in Sweden 1996-
2002, by route of transmission. Absolute 
numbers on Y-axis. (MSM = men who 
have sex with men, PWID = people who 
inject drugs). 
 
 
 
Patients infected in Sweden were less likely to be late testers, in comparison with the total of 
other patients (35 vs. 53%, p<0.001). A significant difference also remained when the 
comparison was restricted only to those born and infected abroad (35 vs. 46%, p<0.05) 
(results not shown), and foreign origin as an important factors associated with late HIV-1 
diagnosis, described by others [110, 163, 164], thus confirmed. Interestingly, for Swedish 
born patients infected abroad, predominantly represented by heterosexual men infected in 
Asia, a significantly increased risk of testing late were seen in comparison with others (61 vs. 
42%, p<0.002), but also in a comparison including only those patients born and infected 
abroad (61 vs. 46%, p<0.05), indicating a low awareness or ignorance in this group.  
Over the study period the proportion of late testers born abroad increased from approximately 
one quarter in 1996 to more than half in 2002, as a result of a decreasing AIDS incidence 
among Swedish-borne patients, but also in absolute numbers the late testers born abroad 
showed an increasing trend (Figure 13). 
 
Figure 13. Late testers in Sweden 1996 
-2002 by origin. Absolute numbers on 
Y-axis. 
 
 
 
 
6.1.2 A need for further studies 
In this study, one of the first national studies on late HIV-1 diagnosis in the era of cART and 
the first in Sweden, we found evidence confirming that late diagnosis was a remaining 
problem and that the group without previously known HIV-1 infection represented an 
increasing part of all cases of AIDS. We found age greater than 40 years, heterosexual route 
of transmission and foreign origin to be significant risk factors for being a late tester 
whereas intravenous drug use was associated with a highly significant reduced risk.  
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In our characterization of the patients with late HIV-1 diagnosis we made a comparison with 
all patients, whom had developed AIDS, after an early diagnosis during the same period.  
Others had made similar comparisons [111, 112] and Castilla [110], whom had published the 
first national study on late diagnosis post-cART in 2002, inspired us to use AIDS as the 
denominator. In retrospect it would have been preferable to use all patients diagnosed early as 
the control group, as we choose to do in paper II-III, to be able to assess the characteristic of a 
patient with a late, as a contrary to an early, diagnosis.  
Additional weaknesses to be discussed are related to the possibility to test anonymously for 
HIV in Sweden and the fact that patients tested HIV positive are reported by a non-unique 
code; if a patient had been tested HIV positive earlier, but turned up several years later with 
an AIDS defining condition, without disclosing the earlier test, we would not have known 
about it. Likewise, we would not always have known if a migrant with AIDS had had a 
previous test before immigration. Finally, the national register of HIV and AIDS, used for the 
study, contained limited data on the date of immigration of migrants, which prevented us to 
evaluate whether the late diagnosis could simply be explained by the patients being severely 
immunocompromised and ill already at arrival or if the AIDS diagnosis could be explained 
by a delay in diagnosis in Sweden. 
On the contrary to many countries, where HIV is not a notifiable disease, this study had the 
strength of being based on a central reporting system, where Swedish physicians were 
obliged to report both HIV and AIDS, separately. This minimized the risk of missing any 
cases and also gave reliable figures on the time between HIV and AIDS. The questionnaire, 
used to collect additional information after the initial reporting, also contributed to fewer 
mistakes and missing data.  
Despite weaknesses in the study two important statements could be made; Late HIV-1 
diagnosis was identified as a true problem in Sweden and there was no evidence of a 
decreasing trend. We could also conclude that the proportion of late testers born abroad was 
continuously increasing. From an infectious disease control and medical perspective I found 
it important to study this area further to assess what measures are needed for an earlier 
identification and care of our patients. 
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6.2 PAPERS II-III 
6.2.1 Patients included  
For these studies we included patients with newly diagnosed HIV-1 infections, prospectively 
identified, directly from the Swedish HIV clinics, rather than from a retrospective register. 
The regional Ethics committee in Stockholm gave us the permission to use unidentified data, 
from the InfCare database, for all patients during the study period. Thus all 575 newly 
diagnosed patients at the twelve study clinics could be included in the study and the 
representativeness of our cohort evaluated. A comparison with all patients linked to Swedish 
HIV Care during the study period (n=827), showed no significant differences regarding 
demography indicating that our data was representative of the country as a whole. (Figure 8). 
Most study patients, 71%, participated in the sub-study with the questionnaire. Reasons for 
not participating were; rejection 11%; medical 7%, loss to follow up 6%, and logistic 5%. For 
Swedish born patients, of whom 78% participated, there was no significant difference 
regarding demographics between those who participated or not. For migrants, of whom 67% 
participated, those estimated to be infected in East or SSA were more likely not to take part 
than those infected in Sweden [OR 3.2 (95% CI: 1.4-7.1); OR 2.9 (95% CI: 1.4-5.9), 
respectively] (data not shown). However, these groups were still well represented, with just 
above 60% recruited from each group. 
For 98% (n=566) of the patients the first CD4+ T-cell count was within 3 months, for 1% 
(n=6) within 6 months. All CD4+ T-cell counts were drawn while the patient was still 
untreated with ARV. For 1% (n=3) it was missing, but due to a recorded PHI (n=1) or AIDS-
diagnosis (n=2) all patients in the study could be successfully classified according to “LP-
status”. Comparing this between patients, participating in the sub-study and not, no 
significant differences were seen.  
Baseline demographics are depicted in Table 1a, Paper II. In summary two thirds of the 
patients were male. Median age at diagnosis was 40 years. Heterosexual route of transmission 
dominated (54%), one third was MSM and 5% infected through IDU. About one third 
originated from Sweden, an additional one third from sub-Saharan Africa and the remaining 
from all parts of the world but predominantly Thailand. A similar pattern was found for route 
of transmission, but with patients infected to a little lower extent in the SSA in favor of the 
Asia and Pacific. 
 
6.2.2 Late Presentation and advanced HIV disease – key problems 
A majority, in total 58% (331/575), of all newly HIV-1 diagnosed patients were Late 
Presenters, of whom two thirds (218/331) already had developed an advanced disease; 56% 
(123/218) based on CD4+ T-cell count alone and 44% (95/218) with an AIDS-diagnosis. 
Another Swedish study [132], conducted by the Swedish Institute of Infectious Disease 
control, of patients infected in Sweden or born in Sweden and infected abroad, 2003-2010, 
using so called “BED-tests” indicated that as many as 63% had been infected more than six 
months at diagnosis. Considering the fact that patients of foreign origin, estimated to be 
infected abroad, but still living in Sweden before the diagnosis, were not included these 
results are well in line with ours. 
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Figure 14. The distribution of 
patients in the categories late 
and non-late presenters of 
HIV-1 infection in Sweden 
2009-2012. 
 
 
 
 
 
On the European level also the Collaboration of Observational HIV Epidemiological 
Research Europe (COHERE) study have reported consistent results with >50% of newly 
diagnosed patients in Europe fulfilling the definition of Late Presentation and as many as one 
third with an advanced HIV disease, when presenting for care [1]. 
Even though there are numerous initiatives and interventions to promote earlier diagnosis 
there has been limited success. A large meta-analysis of studies evaluating the first CD4+ T-
cell count at diagnosis in resource rich countries showed no meaningful improvement since 
the introduction of HAART in 1996 [189]. Similarly a small decreasing trend of LP in 
Europe, by 4% yearly, 2000-2010, reported by COHERE [1], has halted with no change over 
the last years [190]. Also the proportion of persons with advanced disease or AIDS have 
remained stable [190]. Splitting the data into different transmission groups and regions 
however shows a tendency of a slight decrease of LP in the North of Europe whereas LP 
among PWID is becoming more prominent.  
In Sweden a recent “post-study” compilation of national data 2009-2014, without exclusion 
of PHI or those already known to be infected, shows no changing trend in late presentation 
(InfCareHIV 20141231 (Figure 15). Clearly a lot remains to be done.  
 
 
Figure 15. Proportion with Late Presentation (non advanced/advanced HIV) and non-Late 
Presentation among patients newly linked to Swedish HIV care 2009-2014. 	
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6.2.3 Late Presentation is associated with age, origin and country of transmission 
At first sight, also confirmed by the analysis on the bi-variate level, the LP were more likely 
to be female than male (66% vs 53%; p<0.01) and older than the non-LP (mean years: 41 vs 
38; p<0.01). The LP also seemed more likely to be heterosexually infected than trough IDU 
or being a MSM, with proportions of LP of 67, 43 and 40%, respectively (p<0.01). There was 
also a significant difference according to origin with the proportion of LP ranging from 81 
and 74% respectively in patients from Asia and the Pacific and the SSA regions compared to 
43% in patients born in Sweden.  
In a multivariable analysis, adjusted for all demographic variables (Table 2, Paper II) age, 
origin and country of transmission remained significant, but no association was found neither 
for gender nor route of transmission. For advanced HIV a borderline reduced odds were seen 
for MSM (0.6 (0.3-1.0, p= 0.059) and it is possible that an association with reduced odds 
would have been identified if we had had a larger study-population. Still 40% of MSM were 
LP indicating a problem with late diagnosis in all transmission groups, which must be taken 
seriously. 
 
6.2.3.1 Age 
The single factor most associated with late presentation was age, with a continuous increase 
from OR 1.6 (1.0-2.7) if 31-40 years to 4.0 (2.1-7.6) if >50, compared to those <30 years. A 
similar, but even stronger, association with age was seen for patients presenting with an 
advanced HIV disease. Similar results have been presented in other studies suggesting a low 
perception of risk, both among patients and health care professionals [168, 191-196], whom 
often assume sexuality to be an insignificant part of an older patients life [197], as one main 
explanation. 
To find age associated with late presentation is not surprising considering that an infected and 
undiagnosed patient naturally progress in immunodeficiency when they get older. However 
this is clearly not the entire explanation and there are British studies suggesting that nearly 
half of HIV-1 positive individuals > 50 years acquire their HIV infection at age 50 and over 
[198]. An American survey also suggests that three quarters of individuals 57-64 years of 
age, just above half of those 65-74 years of age and one quarter of those 75-85 years are 
sexually active [199]. Additionally around 10% of 57-85 year olds have reported a new 
sexual relationship the last five years [200].  As for HIV and late diagnosis a recent study 
assessing new HIV-1 diagnosis at autopsy also found age ≥65 years as the strongest correlate 
for this [201]. 
The 17% of patients >50 years in our study population represents one of the higher 
proportion of older patients reported in Europe [202]. Since age is associated with a faster 
disease progression of HIV [198] a special focus on timely diagnosis and care is needed in 
this group.  
 
6.2.3.2 Origin and Country of transmission 
Apart from age late HIV-1 diagnosis was associated with origin and country of transmission. 
Increased odds of LP were seen in patients originating from the East [OR 3.5 (95%CI: 1.8-
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6.9)] and the SSA [OR 2.7 (1.4-5.5)], compared to those born in Sweden. Additionally there 
was an independent association also with the country of transmission, with increased odds for 
those infected in the SSA [OR 2.6 (1.3-5.3)] and for those with an unknown place of HIV 
acquisition [OR 3.8 (1.6-9.2)].  
It is well documented that patients of Asian, black African and South American ethnicity 
have a higher probability to be diagnosed late [196, 203]. Creating an additional variable, 
including simultaneously both origin and country of HIV transmission, similar to what we did 
for paper I, however showed interesting results. A comparison of the patients born and 
infected in Sweden (22%) and those born abroad and infected in Sweden (11%), while still 
adjusting for age and route of transmission, showed no significant difference between the 
groups, indicating that the ethnicity might just not hold as an explanation. Comparing instead 
those born and infected in Sweden with migrants reported to be infected abroad (50%) a 
higher odds [OR 3.2 (95%CI: 1.9-5.6)] of being a LP were found for the latter group. The 
patients born in Sweden and infected abroad (10%) did not differ significantly from those 
infected in Sweden and the higher probability of a late HIV-1 diagnosis in this group, reported 
in paper I, thus no longer found.  
Even if there was a considerable lower probability of late diagnosis for all patients infected in 
Sweden and for those Swedish born infected abroad, still as many as 41% of these were LP. 
 
6.2.3.3 Determinants of Late Presentation for patients born in Sweden 
Considering the more detailed data collected in the sub-study, age >50 years [OR 7.8 
(95%CI: 2.0-31.2)] and unknown country of transmission [OR 15.3 (95%CI: 1.7-141.3)] 
were associated with being a LP for Swedish born patients. Patients with a psychiatric illness 
had reduced odds [OR 0.2 (95%CI: 0.1-0.6)], compared to those who had not. Comparing 
instead patients with advanced HIV disease (LPAH) with non-LP (nLP) the association with 
age was even more prominent [OR 15.5 (95%CI: 1.7-137.7) if 41–50 years old and 23.6 
(95%CI: 2.6-215.8), if >50 years old]. Also the association with unknown country of 
transmission [OR 12.8 (95%CI: 1.2-138.1)] and with psychiatric illness [OR 0.2 (95%CI: 
0.0-0.7), p<0.05] remained. Results were adjusted by missed HIV-associated symptoms. 
(Table 3a, Paper II). 
The finding of a lower probability of late diagnosis among patients with psychiatric disease 
has, to our knowledge, not been described before. Possible explanations could be the 
tendency among physicians to primarily offer tests to patients perceived to be at high risk and 
also to those most likely to accept a test [204] in combination with more frequent health care 
contacts in this group. 
 
6.2.3.4 Determinants of late presentation for migrants 
For migrants participating in the sub-study age was also associated with being a LP, with 
increasing odds by each age category [OR 2.2 (95%CI: 1.1-4.6) if 31–40 years to an OR 4.2 
(95%CI: 1.3-14.3) if >50 years, compared to <30]. An increased probability to be a LP was 
also seen for those patients who had spent less than two months in Sweden at diagnosis [OR 
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3.2 (95%CI: 1.1-9.4)] in comparison with those who had lived in Sweden for five years or 
more. The model was adjusted for country of origin and country of transmission. 
Comparing instead LPAH with nLP and adjusting for psychiatric illness, similar, but more 
pronounced associations were seen for age >30 years and time spent in Sweden, both for less 
than two months [OR 3.8 (95%CI: 1.1-12.2)] and 1–5 years [OR 2.7 (1.0-7.0)], compared to 
> five years. Also for patients with country of transmission stated as SSA [OR 3.8 (95%CI: 
1.4-10.4)] or the East [OR 3.6 (95%CI: 1.2-10.9)], compared to Sweden, and for those with 
previously missed HIV-associated symptoms [OR 3.4 (95%CI: 1.4-8.0)], compared to those 
without, an increased probability of presenting late was seen. (Table 3b, Paper II). 
 
6.2.4 Missed opportunities 
In our studies we investigated three kinds of missed opportunities: missed opportunity to test 
at immigration; the “doctors’s delay”: missed at presentation and “patient’s delay”: 
symptoms neglected by the patient. Altogether 65% of the patients, whom had participated in 
the sub-study with the questionnaire (n=409), had at least one missed opportunity. 
 
6.2.4.1 Missed opportunity at immigration 
The greatest of missed opportunities was the missed opportunity to test at immigration, which 
was seen in two thirds (168/253; 66%) of all migrants. Of these 54% were born in the SSA 
and 28% in the East (predominantly Thailand), i.e. regions with a high HIV-1 prevalence 
(data not shown). Additionally we found that half (56%) of all migrants had lived more than 
one year in Sweden at diagnosis. Interestingly only one patient, of those offered a test at 
immigration, reported to have declined the test. (Data not shown). 
The above could partly be explained by the fact that health examinations in Sweden 
predominantly have been offered to refugees and not those immigrated due to family 
connections or work, but there have also been problems with the structure and coordination 
between county councils and reports from the Public Health Agency of Sweden have 
suggested that only 40% of those entitled to health screening actually have been reached 
[205].  
For further results about the association between a missed opportunity at immigration and late 
HIV-1 diagnosis in the migrant population, see 6.2.7 below. 
 
6.2.4.2 Missed AIDS- and HIV-associated conditions at presentation for care 
Details on the missed presentations are depicted in Figure 1a-c, Paper III. In total 27% 
(112/409) of patients had presented for health care services with at least one AIDS- and/or 
HIV-associated condition, without that an HIV-test had been performed. The more serious, 
AIDS defining events (n=31), were seen in 6% (23/409), predominantly in primary care 
(55%). Most common were the unspecific wasting syndrome (n=14), followed by candida of 
the oesophagus (n=9), but there were also odd numbers of the more HIV specific Kaposi 
sarcoma, PCP and PML. One quarter (104/409) of patients (26% of LP; 25% of nLP) had 
presented at least once, with one or more HIV associated conditions (n=162). Whereas 
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seborrhoea (n=19) and oral candida (n=18) were the most common conditions in LP, another 
STI (n=22) and PHI-like illness (n=18) dominated among the nLP. Just like for missed 
AIDS-defining conditions most missed presentations were seen in primary care (58%), but a 
substantial proportion were also in STI/skin clinics (16%).  
Other studies, from countries like Denmark, Italy, the UK and Scotland [167, 168, 206, 207], 
have reported missed opportunities to diagnose HIV at similar levels as ours. In a recent 
Dutch study comparing newly diagnosed with HIV-negative controls, 62% had visited their 
GP the prior year, compared to 39% of controls and as many as 59% had presented with an 
indicator condition during the five previous years, compared to 7% of the controls, [208]. 
Another, French, study reported that 82% of those newly diagnosed who had presented for 
care the three previous years had not been offered testing and neither had a majority of MSM, 
despite reporting their sexual orientation [179]. 
 
6.2.4.3 Patients missed at presenting for care 
In a multivariable regression model, adjusted for route of transmission, patients from the 
East or SSA had reduced odds of missed presentations (OR 0.4; 95% CI: 0.2-0.8, p<0.05; 
OR 0.3; 95% CI: 0.2-0.6, p<0.001, respectively) compared to patients born in Sweden. A 
borderline reduced odds was also seen for patients from Other countries (Western Europe, 
North and Latin America, Caribbean, North Africa, Israel, Middle East) indicating that 
being Swedish born was the most important factor associated with a missed HIV diagnosis 
while presenting for care.  
It is well known that HIV-tests are primarily offered to those perceived to be at high risk 
[204] and the above consequently indicates a good adherence to one of the most prominent 
epidemiological risk factors, foreign origin [167]. Somewhat surprising we did not find any 
association with route of transmission, where a reduced risk to be missed for MSM could 
have been anticipated. Probably this could be explained by sexual orientation not being as 
obvious to the physician as an origin from epidemic area and seldom asked for, but as 
mentioned above MSM have also been reported to be missed despite reporting their sexual 
orientation [179].  
 
6.2.4.4 Missed presentations and late HIV-1 diagnosis 
In our study the probability to have an earlier missed presentation was twice as high among 
LP with advanced HIV compared to non-LP (OR 2.0; 95% CI 1.2-3.1, p<0.01) and 
consequently there was also a significantly lower median CD4+ T-cell count at diagnosis 
for those who had a missed presentation; 150 versus 290 cells/mm3, p=0.0001 (Figure 16). 
If testing, on the other hand, is performed at presentations with indicator diseases a reduction 
in LP, with as much as 50%, have been described in those tested compared to those not [207]. 
With one quarter of nLP reporting missed presentations in our study it is evident that great 
improvements could be possible. Furthermore our study-design, where we restricted the 
medical history to the previous three years and to a predefined list of HIV-associated 
conditions, most likely made us underestimate the extent of the problem indicating that even 
greater accomplishments could be made. 
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Figure 16. CD4 count at diagnosis in 
patients without (No) and with (Yes) a 
missed HIV test when presenting for 
health care. *Wilcoxon test shows a        
significant difference. 
 
 
 
 
 
It is obvious that the predominant strategy of risk factor based HIV testing, traditionally used 
in Europe, fails to identify many patients. Most of the HIV-associated conditions used in our 
study has also been evaluated in the HIDES-study and proved to exceed the 0.1% needed to 
reach cost effectiveness of general screening [166]. However, despite demonstrated as 
appropriate triggers for HIV testing a lot remains to be done to make the use feasible in 
Europe, were testing rates in well established indicator conditions were still low in 2013 
[209]. 
 
6.2.4.5 Patient´s neglect 
Sixty-five patients (16%) in our study had a history of 92 neglected AIDS- and/or HIV -
associated symptoms the three years prior to their diagnosis. For LP, the most commonly 
neglected symptoms were weight loss (19%) and fatigue (15%). Among nLP a “PHI like 
syndrome” was most common, definitively described by 38% and possibly by additional 35% 
(data not shown).  
Just as for the missed presentations, at seeking health care, the probability of neglecting 
symptoms was lower among patients originating from the East (OR 0.3; 95% CI: 0.1-1.0, 
p<0.05) and the SSA (OR 0.4; 95% CI: 0.2-0.8, p<0.05) compared to patients born in 
Sweden. A lower probability of neglecting symptoms was also seen for MSM (OR 0.5; 95% 
CI: 0.2-1.0, p<0.05) compared to those heterosexually infected.  
As far as we know ours is the only study describing the patients who experience symptoms 
without seeking health care, but it is well in line with other studies describing a low 
perception of risk for HIV as one of the greatest barriers to testing [175, 180]. Even though 
our use of an open question, allowed for all kinds of HIV-associated symptoms to be 
reported, the three-year time frame most likely resulted in an underestimation of symptoms. 
However the low number, in comparison with the missed presentations for care could 
indicate that barriers to testing is larger on the provider level, also described by others [204].  
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6.2.5 The initiator of HIV-testing 
In our study a health care provider initiated 75% of all HIV-tests that lead to a diagnosis, 
whereas the patient was the initiator in 25%.  
Of the provider initiated tests 44% were due to symptoms and 56% due to different kinds of 
screening (screening in high prevalent groups 31%; contact tracing 15%; maternal 
health/blood donors 10%). The median CD4+ T-cell count at diagnosis were significantly 
lower count for those patients tested due to symptoms compared to those whom had been 
the subjects of screening (110 vs. 300 cells/mm3), irrespective of PHI and other early 
symptoms also being included in this group. The highest CD4, however not significantly 
different from those diagnosed through screening, was seen for those tested on their own 
initiative, 375 cells/mm3 (Figure 17). 
Figure 17. CD4+ T-cell 
count at diagnosis, divided 
by the initiator/reason of the 
HIV-test. The Kruskal Wallis 
test shows a significant diffe-
rence comparing group 2 
with group 1, 3 and 4. 
 
 
 
 
 
A difference was seen for gender with men more likely to take the initiative to test (33% vs. 
14% in women), whereas women were more likely to be diagnosed through screening (57% 
vs. 33% in men), p<0.001. This difference could to a large extent be explained by MSM often 
tested on their own initiative (33% vs. 19% of heterosexuals, p<0.001) and many women 
tested due to maternal screening (18%). The proportion of patients tested due to symptoms 
increased with age (from 28% among those <50 years to 56% among those >50 years, 
p<0.001). Whereas most of the Swedish born patients were diagnosed due to symptoms 
(39%) and almost as many due to testing on their own initiative, the majority of patients from 
the SSA (65%) were diagnosed through screening and only 12% through an own initiative to 
test. For patients from the East the initiator of the test was equally distributed.  
 
6.2.5.1 Patients whom take initiative to test for HIV 
In a multivariable analysis assessing the patient as the initiator of the HIV-test patients 
infected in the East, with a history of drug use or a previous negative HIV test (predominantly 
seen among MSM) were more likely to take the initiative, whereas patients older than 50 
years and those with a history of a previous missed presentation had reduced odds, p<0.05. 
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This could indicate both an increased awareness in the prior groups, but also better 
availability to test in terms of STI clinics and drug addiction treatment centres [104]. 
The low probability to initiate a test among individuals with a missed presentation is 
important and indicates that a missed presentation could have further implications than just 
that of one missed opportunity. Since many patients believe that a HIV-test is routinely 
performed, whenever they have their blood drawn [210], or as they often have stated to me: 
“It should have shown in the blood somehow, should it not?”, a missed presentation could 
give the patient a false sense of not being seriously ill and thus possibly delay further health 
care contacts. 
 
6.2.6 Increasing HIV testing 
Serious attempts to increase HIV testing have been made throughout Europe. In the UK the 
national HIV guidelines in 2008 recommended HIV testing to be considered both in general 
practice and at all general medical admissions in regions with a HIV-prevalence exceeding 
two per 1000 [211]. The following year a one-time voluntary HIV screening test was 
recommended for the whole population in France [170]. However the adherence to these 
guidelines have proved to be difficult, both due to general feasibility and to economical 
issues [179, 212], even though there are a few good examples [213-215]. 
Our studies indicate that both awareness of HIV and availability to test are important 
factors to enhance earlier diagnosis. We can also conclude that the screening activities 
performed in Sweden today catch patients at an earlier stage of disease than if the patients 
are diagnosed when presenting for health care with symptoms. Whereas it has been 
described that physicians are more likely, and comfortable, to offer a test in a screening 
setting than due to an indicator condition the opposite has proved to be true for patients, who 
are more likely to accept testing if being symptomatic [204]. To launch the Indicator 
Conditions, elaborated by the HIV in Europe initiative [165], as triggers for “screening” thus 
seems to be a possible way forward. This kind of opt-out approach, when the patient is 
informed that a HIV test will be included as one in a standard batch of tests and that they 
specifically need to state if they do not want to be tested has been associated with higher 
rates of testing both compared to opt in approaches and surprisingly also mandatory testing 
[104]. 
That routine screening, without singling out specific patients, is efficient has been shown, not 
the least in antenatal screening where both uptake and acceptance are very high [165]. 
Hopefully an implementation of routine screening at certain conditions will be more feasible 
to use within Swedish health care, than the predominantly used “risk-factor” based testing, 
even though screening in high prevalent groups naturally should not be forgotten.  
 
6.2.7 HIV-1 diagnosis in migrants 
Even though individuals from high prevalence countries, predominantly from the SSA, 
constitute a substantial proportion of the HIV-1 positive individuals in Europe [88] and as 
many as one third of newly HIV-1 diagnosed in the EU/EEA region are born abroad, 
information and data on HIV prevalence, incidence and post arrival acquisition of HIV 
among migrants are scarce [216].  
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In our study of newly HIV-1 diagnosed patients (papers II-III) almost two thirds were born 
abroad, which represents one of the higher proportions described in Europe [168, 192, 193, 
195, 196]. We also concluded that this group represents a particularly vulnerable group, not 
only to HIV itself [217], but more specifically so to late presentation (65%) and advanced 
HIV disease (43%), also reported by others [168, 192-196, 218, 219]. In total almost three 
quarters of all LP (74%), and LPAH (73%), were born abroad.  
Whereas 17% of the migrants were reported to have acquired their HIV-1 infection in 
Sweden, the vast majority were reported to have been infected abroad and it could easily be 
claimed that late presentation is not a major national problem, but rather explained by patients 
being severely ill upon arrival and possibly already aware of their diagnosis. To further 
investigate this we modelled the time resident in Sweden, for those migrants estimated to be 
infected abroad, with the probability of Late Presentation and Advanced HIV (6.2.7.1) as well 
as with the reason for testing (symptoms/patient’s initiative/screening) (6.2.7.2) up until five 
years after arrival.  
 
6.2.7.1 Time in Sweden and the probability of a late HIV-1 diagnosis 
For those patients tested within two months of arrival the probability to be a LP or LPAH was 
80% and 50% respectively. The proportion of LP, particularly the LPAH, then decreased to 
further increase again from four months and then continuously increase until three years after 
arrival. A similar, but even more pronounced pattern, were seen analysing only the patients 
from SSA, who represented the majority of patients. For patients from the Asia and Pacific 
region, the probability of being a LP at time of arrival was 70% with a small increase during 
five years after immigration and a doubling of the probability to be a LPAH (from 40% to 
80%) during the first three years, which then became stable.  
Interestingly an overall increase in nLP was seen after three years. Whether this was due to a 
“survival of the fittest”, so called slow progressors, or could be explained by infections 
actually acquired after immigration is uncertain. Against the prior speaks the fact that this 
tendency was seen in patients from the SSA and not from the Asia and Pacific region. To 
analyse the latter we took the initiative to paper IV, see 6.3 below. (Figure 18.A). 
 
6.2.7.2 Time in Sweden and the reason for HIV testing 
For all migrants screening, primarily through health examinations, dominated as the reason 
for HIV testing the first year after arrival whereas the probability to be tested due to 
symptoms continuously increased from very low levels to 50% two and a half years after 
arrival and then remained stable. Overall the patient’s initiative to testing was low, but more 
common at arrival (25%) and at two years after arrival. This lack of initiative may reflect 
difficulties with access to health care, lower socioeconomic status or increased stigma in 
these groups [103]. It also dismisses speculations of immigration due to HIV-1 related illness 
per se. Also, a finding that drug resistance in major as well as in minor quasipecies can be 
detected only in a minority of patients at diagnosis, suggests that few of the migrants have 
been treated before [220].  
More specifically, for patients from the SSA >80% of those diagnosed within the first months 
after arrival were identified through screening. The detection rate through the screening 
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procedure then continuously decreased to 40% after three years, while testing due to 
symptoms instead became dominating. After three years, screening once again became the 
main testing cause. Overall the patient initiated testing was low, around 20%. 
Among patients from the Asia and Pacific region half of those tested the first months after 
arrival took the initiative to test, but there was then a decline to a very low percentage after 
three years. A similar patter was seen for screening, whereas the probability to be diagnosed 
because of HIV/AIDS-related symptoms increased from less than 20% to almost 100% after 
40 months. (Figure 18.B). 
 
 
Figure 18.  Migrants infected outside Sweden: Proportions of late presenters (LP) with non-advanced 
(LPnAH) or advanced (LPAH) disease and non-LP [A] and reason for HIV-testing [B], in relation to 
time in Sweden, at diagnosis. 
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6.3 PAPER IV 
The evidence from Paper II, that half of all migrants had lived >1 year in the country at 
diagnosis and that two thirds had not been tested at immigration, implied that there is a 
breeding ground for HIV-1 transmission in Sweden and that the domestic infections might be 
higher than reported. Our modelling of the time resident in Sweden, that showed a trend 
towards a higher proportion with early diagnosis three years after arrival, for those migrants 
estimated to be infected abroad [221], was also well in line with this possibility. In addition, a 
sequence analysis of circulating HIV-1 strains, among patients reported to be infected in 
Sweden, have shown an increasing proportion of non-B subtypes and new recombinant 
forms, in favour of the HIV-1 subtype B, which has dominated the epidemic in Europe from 
the beginning [28]. With the predominance of migrants in Paper II-III in mind and to further 
assess whether the number of domestically acquired infections is underestimated we applied 
the CD4+ T-cell decline trajectory model (see 5.2) to the Swedish migrant cohort. 
 
6.3.1 Patients included 
A total of 1244 patients were included. Baseline characteristics are depicted in Table 1, Paper 
IV. In summary mean age at diagnosis was 36 years and 55% were females. 72% were 
heterosexually infected and 13% were MSM. Patients were predominantly born in Africa 
(63%), 10% in Europe and the remaining in other parts of the world. Median CD4+ T-cell 
count at diagnosis was low, 240 cells/mm3. After excluding patients resident less than six 
months in Sweden in a sensitivity analysis, similar characteristics were found for the 
remaining 655 patients, with the exception that the proportion born in Africa decreased from 
63% to 54% while those born in countries other than Africa and Europe increased from 27% 
to 35% (data not shown). 
 
 
 
 
 
 
 
 
 
Figure 19.  Flowchart for inclusion of patients in Paper IV. 
All patients in InfCare ≥ 15 years old 
n= 9,390 
Migrants 
 n=5,764  
MTCT or PHI  
 n=51  
Documented date of  
immigration, age and first CD4+ T-cell count 
 n=1,295  
Born in Sweden 
 n=3,626  
Immigration within six months of diagnosis 
 n=589 
Unknown date of  
immigration, region of birth, age or first CD4+  
T-cell count before starting treatment 
 n=4,469  
Patients included in the main study 
 n=1,244 
Patients included in the sub study 
 n=655  
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6.3.2 The CD4+ T-cell decline trajectory model suggests a higher rate of HIV-1 
acquisition post immigration  
By applying the CD4+ T-cell trajectory model to our migrant cohort, with a known date of 
immigration, we received estimates of the time of seroconversion, which we compared to the 
reported date of immigration in order to estimate whether the patient was infected after arrival 
to Sweden or not. In total the model estimated 17% to be domestically infected and 74% 
infected outside, while the corresponding figures registered in InfCare was 11% and 89% 
respectively. For 8% of the patients the model estimate was uncertain (Table 4).  
The estimates of the model and the doctors, documented in InfCare HIV, were concordant for 
the majority of patients (81%)*, but in 11% they disagreed**. More commonly this was due 
to the model estimating the patients to be infected after arrival to Sweden while the patient 
was reported by the doctor to be infected abroad, than vice versa (9.4 vs 1.2%). 
Doctor´s	estimate	n	(row	%)	 Algorithm	estimate	 Total	n	(col	%)	Sweden	 Outside	Sweden	 Uncertain	Sweden		 100	(8.0)*	 15	(1.2)**	 18	(1.5)	 133	(10.7)	Outside	Sweden		 117	(9.4)**	 909	(73.1)*	 85	(6.8)	 1,111	(89.3)	Total	 217	(17.4)	 924	(74.3)	 103	(8.3)	 1,244	(100)	
Table 4: Doctor and algorithm estimates of probable country of infection among 1,244 
migrants aged 15 or above, without MTCT or PHI, diagnosed with HIV-1 in Sweden with 
known year of arrival. 
 
To further assess which of the estimates were most likely to deliver accurate results we 
performed phylogenetic analysis on viral sequences from the patients of whom the estimates 
were discordant. Even though there were some weaknesses associated with this analysis, 
which were performed anonymously on 70% of the patients who had discordant estimates, 
the phylogenetic analysis indicated a higher concordance with the model estimate than with 
the estimate of the clinical reports (30% vs. 17%).  
In the sensitivity-analysis (excluding patients resident less than six months in Sweden at 
diagnosis), the model and the doctor’s estimate of infection in Sweden increased to 32 and 
20% respectively, whereas the uncertainty for the model estimate rose to 14% (data not 
shown). The majority (93%) of all patients with a discrepancy between the model and 
doctor’s estimates remained and the results of the phylogenetic analysis still favoured that of 
the model (28 vs. 18%).  
 
6.3.3 Determinants of the patients with conflicting estimates of the country of HIV-1 
acquisition 
To investigate socio-demographic factors associated with a discrepancy between the doctor’s 
reported country of HIV-1 acquisition and the model estimates we performed two 
multinomial regression models. The first model, assessing the discrepancy doctor 
out/algorithm in instead of agreement, found that the probability of discordance increased 
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with age [OR 8.1 (95% CI: 1.8-37.2), if 35-44 years, OR 13.2 (2.7-64.3) if 45-54 years and 
OR 15.8 (3.0-82.5) if >55 years; p<0.01), compared to those 15-24 years old] and higher 
CD4+ T-cell count at diagnosis [OR 7.1 (3.6-14.1), if 350-499 cells/mm3 and OR 9.4 (4.8-
18.5) if ≥ 500 cells/ mm3; p<0.001), compared to less than 200 cells/mm3]. For PWID there 
was a decreased likelihood of discordance [OR 0.1 (0.0-0.6); p<0.05), compared to patients 
heterosexually infected], just like for those with a later the year of arrival [OR 0.4 (0.2-0.7), if 
2000-2004, OR 0.1 (0.1-0.3) if 2005-2009 and 0.0 (0.0-0.0), if ≥2009; p<0.005), compared to 
those that arrived before the year 2000]. There was no association with gender or region of 
birth, but the latter were kept in the model and adjusted for.  
The second model, assessing the discrepancy doctor in/algorithm out, included only 15 
patients and no significance was found. In the sensitivity-analysis, the determinants were 
equivalent to the above. 
 
6.3.4 The CD4+ T-cell decline trajectory model – a valuable tool in HIV-1 
surveillance 
Of all migrants registered in the InfCare database 12% are reported to be infected in Sweden. 
In our recent studies, Paper II-III, assessing only the newly diagnosed patients, the proportion 
raised to 17%. Further assessment, by application of the CD4+ T-cell trajectory model to 
Swedish data, indicates that these estimates, based on clinically reported country of 
transmission, are likely to be underestimations and highlights the difficulty in estimating the 
country of HIV acquisition, also described by others [89, 90, 96].  
The relatively high, 81%, concordance between the model and the doctor’s estimates and the 
additional phylogenetic analysis, favouring the CD4 model, indicate that the model is a well 
functioning tool and produces reliable estimates. As a contrary to physicians, who might be 
biased to assume a patient from a high prevalent country to be infected in their country of 
origin [90] and to have been infected for a longer duration than is actually true, due to a 
natural lower CD4+ T-cell count [181, 182, 222, 223], the CD4 model accounts for this and 
has the advantage to produce more objective estimates.  
The CD4 model only estimates whether a patient has become infected before or after arrival 
to a country, not the geographical place of transmission. Thus, it does not account for the 
possibilities of travels abroad after immigration. However, since the model estimate is the 
time of seroconversion rather than the country of HIV acquisition, it is possible that for some 
patients both estimates could be right; that is when the patient got infected after immigration 
(model’s estimate), but while going abroad (doctor’s estimate). The high proportion (52%) of 
patients with a discrepancy, where the phylogenetic analysis did support neither of the 
estimates, and the higher probability to have a discrepancy at higher CD4+ T-cell counts (that 
is a more recent infection) are also well in line with this.   
In conclusion our analysis showed that the CD4 method has a good precision in estimating 
the time of HIV acquisition and confirms the hypothesis that a higher proportion becomes 
infected after arrival than previously suggested. Independent on whether the infection is 
acquired in Sweden or while going abroad, after immigration, it is important to further 
emphasize primary preventive measures among migrants who have established themselves in 
their new home country.    
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7 GENERAL SUMMARY AND DISCUSSION 
 
In Paper I, which was one of the first national studies on late HIV-1 diagnosis after the 
introduction of cART, we found evidence of an increasing proportion of patients with 
simultaneous HIV/AIDS diagnosis in Sweden, including a growing number of migrants in 
this group, based on retrospective data.  
For Papers II-III instead, we consecutively recruited newly HIV-1 diagnosed patients from 
clinics throughout the country and merged InfCare data with information in a questionnaire, 
obtained through interviews and reviews of hospital records. In order to allow comparisons 
across Europe we used the new European consensus definition of LP [2]: presenting with 
CD4+ cells <350/mm3 +/- AIDS. This definition has been criticized to overestimate the 
prevalence of LP [224], particularly in MSM, due to the frequent occurrence of low CD4 T-
cells during PHI. Therefore, as the first study adjusting for this, we defined all patients with 
PHI as non-LP. 
The majority (58%) of all patients were LP, most commonly in migrants but also in Swedish 
born. Notably, half of the migrants had lived in Sweden for >1 year at diagnosis and two 
thirds had a missed opportunity at immigration. Assessment of the time resident in Sweden at 
diagnosis, the stage of disease and the reason for HIV-testing, for those infected abroad, 
highlighted the importance of provider initiated testing and clearly suggested that early and 
more prevalent health examinations could decrease HIV related morbidity and mortality. That 
this is feasible and that the universal HIV screening can be well accepted also in migrants 
from low prevalent countries has recently been shown [225]. 
Many patients had the opportunity to be diagnosed earlier, either having symptoms 
presenting for care without being tested (27%) or experiencing symptoms without seeking a 
doctor (16%). My interpretation of our results is that although there are missed opportunities 
to test many migrants at immigration, the “HIV awareness”, both in health care and among 
individuals, are higher for those belonging to the classical epidemiological risk-groups, 
especially when symptoms evolve. On the contrary to patients with a “risk-behaviour”, who 
are more likely to initiate a test themselves, often at an early stage, many migrants do not 
initiate the test, but seek healthcare, when becoming ill.  
In my thesis I show the importance of HIV testing not only in those with a perceived risk but 
also in everyone with symptoms indicative of HIV. By increased screening at immigration 
and implementation of indicator guided testing, earlier diagnosis and timely ART would be 
possible. 
Paper II-III had a high coverage rate (70%) of all newly diagnosed patients in the country, 
including a substantial proportion of migrants, often not well represented in other studies. In 
contrast to most studies on LP, where CD4+ T-cell counts often are missing, all our patients 
could be characterized according to the European consensus definition [2]. Another potential 
problem is the risk of excluding patients with the most severe disease. Since we allowed 
patients to be included up to 6 months after diagnosis most of them could be included and a 
comparison between those participating in the questionnaire with those, who did not, showed 
no differences regarding LP-status (nLP, LPnAH and LPAH). Well aware that collecting 
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unbiased information from questionnaires is a complex matter, we adjusted for this. The 
questions were based on an extensive literature review and involvement of experts in related 
fields. The physician filled in the answers, in the presence of the patient and if needed, an 
interpreter was used. In order to minimize recall bias the history of missed diagnosis was 
limited to three years, which increased the reliability of the data, but, most likely, made us 
underestimate the extent of the problem.  
For Paper IV, with the predominance of migrants in Papers II-III and reports on the risk of 
underestimating HIV-1 acquisition after arrival to the new country in mind, we decided to 
assess whether this would be true also in Sweden. By applying a CD4+ T-cell decline 
trajectory model to 1244 migrants, with a recorded date of immigration, we produced 
estimates of 17% infected in Sweden compared to only 11% clinically reported. Even though 
just above one fifth of all known HIV-1 positive migrants in Sweden were included, due to a 
high proportion with missing date of immigration, the model could still be evaluated and the 
risk of underestimating domestic infections among migrants confirmed. However, to truly 
estimate the number of infections post-immigration further analysis is needed and planned 
for. 
Considering the fact that a substantial proportion of migrants acquire their HIV-1 infection 
after arrival to Sweden primary prevention adapted for different migrant groups, needs to be 
strengthened in the national prevention program.  
In summary, in order to enhance timely identification and care, HIV testing should be offered 
on a broader basis. Since cost effectiveness have been demonstrated at a HIV prevalence of 
0.1 % [166] this should be feasible. An increased screening in a wider range of settings would 
also be a valuable step in normalizing the HIV screening test and could, as a consequence, 
hopefully contribute to the process of reducing stigma and thereby serve a facilitator for even 
more testing [180].  
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8 CONCLUSIONS 
 
 
§ Late diagnosis is a key problem in the Swedish HIV-1 epidemic 
Ø More than half of the patients are diagnosed late. 
Ø There are no signs of a decreasing trend 2009-2014. 
 
§ The majority of the Late Presenters can be diagnosed earlier with a more efficent 
health care system 
Ø Two thirds of migrants were not offered HIV testing at immigration. 
Ø Half of the migrants had lived > one year in Sweden at diagnosis.  
Ø One quarter of all newly HIV-1 diagnosed patients had presented for health care 
with typical HIV- and AIDS-associated conditions without being HIV tested. 
Ø Almost one fifth of all patients had had HIV- and AIDS-associated symptoms 
without seeking health care.  
 
§ Specific factors increase the risk of late diagnosis 
Ø Older age and foreign origin are the most important factors. 
However, late diagnosis is found among all patient categories. 
Ø Patients without epidemiological indicators of HIV are more likely to have a 
history of missed presentations, to neglect symptoms and are less prone to take 
an initiative to test for HIV. 
 
§ The proportion of migrants infected after arrival is underestimated 
Ø A CD4+ T-cell trajectory model gives a higher estimate than the physician´s 
interview. 
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9 SAMMANFATTNING PÅ SVENSKA 
Trots att effektiv behandling mot HIV har funnits i närmare två decennier är HIV/AIDS 
fortfarande en av de främsta dödsorsakerna i världen. I Europa uppskattas en tredjedel av de 
individer som lever med HIV vara ovetande om sin diagnos och hälften diagnosticeras sent 
med konsekvenser i form av ökad sjuklighet, dödlighet, smittspridning och höga kostnader 
för sjukvård. Syftet med denna avhandling var att analysera omfattningen av sent 
diagnosticerad HIV-1 infektion i Sverige och fastställa vilka som har störst risk att 
diagnosticeras sent och varför.  
I arbete I utförde vi en registerstudie baserad på samtliga patienter rapporterade med AIDS 
(n=487) till Smittskydds Institutet (SMI) 1996-2002, där jag kunde konstatera att patienter 
med sen diagnos (här definierade som samtidig HIV/AIDS) utgjorde en ökande andel av 
individer med AIDS i Sverige. Heterosexuellt infekterade, individer > 40 år och utlandsfödda 
hade alla högre sannolikhet för att diagnosticeras sent.  
I arbete II utförde vi en nationell tvärsnitts- och kohort-studie, där vi löpande inkluderade 
samtliga patienter med nydiagnostiserad HIV-1 infektion vid 12 svenska kliniker. Data 
inhämtades från det nationella kvalitetsregistret InfCare HIV (n=575) och ett för ändamålet 
utarbetat frågeformulär (n=409). Sen diagnos definierades som Late Presentation (CD4+ T-
celler < 350/mm3 +/- AIDS), vilket uppfylldes av 58%. Ålder (med ökad sannolikhet i och 
med stigande ålder) samt icke-svenskt ursprung, vilket sågs hos 65%, var starkt associerade 
med sen diagnos. För utlandsfödda, infekterade i Sverige, sågs emellertid ingen ökad risk 
jämfört med svenskfödda. Hälften av migranterna hade levt mer än ett år i Sverige vid 
diagnos och två tredjedelar hade en missad möjlighet att diagnosticeras i anslutning till 
ankomst. Jag kunde även konstatera att en fjärdedel av samtliga patienter hade missade 
möjligheter inom svensk sjukvård, då de sökt för HIV- och AIDS-relaterade symtom utan att 
erbjudas testning samt att 16% negligerat självupplevda symtom.  
I arbete III analyserade vi vidare de missade möjligheter som sågs i samband med att 
patienterna sökt vård för HIV- respektive AIDS-associerade symtom samt själva negligerat 
sina symtom. Vi analyserade även initiativtagaren till testet som slutligen ledde till diagnos. 
Här kunde jag konstatera att migranter är mindre benägna såväl att ”missas” då de söker vård 
som att negligera egna symtom, jämfört med svenskfödda. Även individer som identifierade 
sig som män som har sex med män (MSM) var mindre benägna att negligera sina symtom än 
heterosexuellt infekterade. Individer som använt droger, testats tidigare (ff a MSM) samt de 
som infekterats utomlands var mer benägna att ta initiativ till testning, emedan individer >50 
år samt de som tidigare ”missats” av sjukvården hade en minskad sannolikhet för detta.  
Övervikten av migranter i arbete II-III, och resultat indikerande att andelen som infekterats 
efter ankomst till Sverige kan vara underskattad, fick mig att vilja undersöka detta vidare. I 
arbete IV applicerade vi en modell, baserad på nedgång i CD4+ T-cells-värde, på den 
svenska migrant kohorten för att kunna jämföra ett modell-estimerat värde på smittland med 
vad som rapporterats kliniskt. Totalt inkluderade vi 1244 patienter varav modellen 
uppskattade att 17% infekterats efter immigration emedan det kliniska estimatet var 11%. För 
de patienter där det förekom en skillnad mellan estimaten utförde vi fylogenetiska analyser, 
vilka påvisade en högre överensstämmelse med modell-estimaten (30 vs 17%).  
Sammanfattningsvis kan jag konkludera att en stor andel av HIV-1 infekterade patienter i 
Sverige diagnosticeras sent, men att vi har många möjligheter att förbättra detta. Aktiviteter 
för att öka den allmänna medvetenheten om HIV, kontinuerligt främjande och normalisering 
av HIV-testning, utbildning av vårdpersonal och vidare implementering kring begreppet 
indikatorsjukdomar liksom en utvidgad testning och primärprevention riktad mot våra 
migranter är samtligt viktiga steg framåt.   
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